As filed with the Securities and Exchange Commission on December 21, 2006
REGISTRATION NO. 333-128670
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT NO. 3 TO
FORM SB-2
REGISTRATION STATEMENT
UNDER THE
SECURITIES ACT OF 1933
MAZAL PLANT PHARMACEUTICALS, INC.
(F/K/A AKID CORPORATION)
(Name of Small Business Issuer in its Charter)
Nevada (formerly Colorado) 2834 20-3761221 (formerly 84-1493150)
-------------------------- ---- --------------------------------
(State or other jurisdiction of (Primary Standard (I.R.S. Employer
incorporation or organization) Industrial Identification No.)
Classification
Code Number)
43 West 33rd Street
New York, NY 10001
(212) 695-3334
(Address, including zip code, and telephone number,
including area code, of registrant's principal executive offices)
Mechael Kanovsky
Chief Executive Officer
Mazal Plant Pharmaceuticals, Inc.
43 West 33rd Street, Suite 405
New York, NY 10001
(212) 695-3334
(Name, address, including zip code, and telephone number,
including area code, of agent for service)
Copies of communications to:
Sam Berkowitz
Secretary
Simcha Edell
Chief Financial Officer
Mazal Plant Pharmaceuticals, Inc.
43 West 33rd Street, Suite 405
New York, NY 10001
(212) 695-3334
Approximate date of commencement of proposed sale to the public: From time to
time after the effectiveness of the registration statement.
If any of the securities being registered on this Form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, check the following box. |X|
If this Form is filed to register additional securities for an offering pursuant
to Rule 462(b) under the Securities Act of 1933, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. |_|
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under
the Securities Act of 1933, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering.|_|
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under
the Securities Act of 1933, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering.|_|
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. |_|
CALCULATION OF REGISTRATION FEE
PROPOSED MAXIMUM PROPOSED MAXIMUM
TITLE OF EACH CLASS OF SECURITIES AMOUNT TO BE OFFERING PRICE AGGREGATE OFFERING AMOUNT OF
TO BE REGISTERED REGISTERED (1) PER SHARE PRICE REGISTRATION FEE
- -------------------------------------------------------------------------------------------------------------------
Common Shares, no par value 10,000,000(2) $0.45 $4,500,000 $414
- -------------------------------------------------------------------------------------------------------------------
Common Shares, no par value 6,295,996(3) $0.55 $3,462,798 $318
- -------------------------------------------------------------------------------------------------------------------
Common Shares, no par value 1,000,000(4) $0.50 $ 500,000(5) $ 46
- -------------------------------------------------------------------------------------------------------------------
Total 17,295,996 8,462,798 $778
- -------------------------------------------------------------------------------------------------------------------
(1) In the event of a stock split, stock dividend or similar transaction
involving our common shares, the number of shares registered shall automatically
be increased to cover the additional shares of common shares issuable pursuant
to Rule 416 under the Securities Act of 1933, as amended.
(2) Represents shares of common stock offered directly to the public by us.
(3) Represents shares of common stock being registered by selling security
holders.
(4) Represents resale of shares of common stock issuable in connection with the
exercise of the warrant. The warrant entitles the holder to purchase one share
of common stock at any time until October 30, 2008 at an exercise price of $0.50
per share.
(5) Stated for the purpose of calculating the amount of the registration fee
pursuant to Rule 457(g)(2) under the Securities Act of 1933. Such price has been
computed based on highest offering price of securities of the same class
included in this registration statement.
The Registrant hereby amends this Registration Statement on such dates as may be
necessary to delay its effective date until the Registrant files a further
amendment which specifically states that this Registration Statement will
thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933 or until this Registration Statement becomes effective on such date
as the Commission, acting pursuant to Section 8(a), may determine.
PRELIMINARY PROSPECTUS SUBJECT TO COMPLETION
DATED December 21, 2006
THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. THE
SELLING SECURITY HOLDER MAY NOT SELL OR OFFER THESE SECURITIES UNTIL THIS
REGISTRATION STATEMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION IS
EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL THESE SECURITIES AND IT IS
NOT SOLICITING AN OFFER TO BUY THESE SECURITIES IN ANY STATE WHERE THE OFFER OR
SALE IS NOT PERMITTED.
MAZAL PLANT PHARMACEUTICALS, INC.
10,000,000 Shares of Common Stock
6,295,996 Selling Stockholders Shares of Common Stock
1,000,000 Shares of Common Stock issuable in
connection with the exercise of a Warrant
The prospectus relates to: (1) the sale by us of up to 10,000,000 shares of
common stock at a purchase price of $0.45 per share for a total amount of
$4,500,000 and (2) to the registration for resale by certain selling security
holders of Mazal of up to 7,295,996 shares of common stock in connection with
the registration for resale of (a) up to 6,295,996 shares of our common stock
that were issued in various transactions exempt from registration under the
Securities Act of 1933 ("Act") at a price per share of $0.55 and a total amount
of 3,462,798 (that may fluctuate) until the securities are quoted on the OTC
Bulletin Board (or a national exchange) and thereafter from time to time at
prevailing market prices at the time of sale and (b) the registration for resale
of up to 1,000,000 shares of our common stock which may be issued upon exercise
of a warrant that was issued in a transaction exempt from registration at a
price per share of $0.50 and a total amount of $500,000 (that may fluctuate)
until the securities are quoted on the OTC Bulletin Board (or a national
exchange) and thereafter from time to time at prevailing market prices at the
time of sale.
This offering is conditioned upon our raising at least $1,500,000. Until a
minimum of $1,500,000 is raised by us by selling our common stock offered in
this prospectus, all payments for shares will be deposited into an escrow
account at Bank Hapoalim New York. The offering by us of our common stock will
be for a period of 180 business days from the effective date. If $1,500,000 is
not raised in within a period of 180 business days from the effective date of
this registration statement, all payments deposited in the escrow account will
be promptly refunded in full, without interest and without any deduction for
expenses. Once $1,500,000 is raised in this offering by us, all funds held in
escrow will be released to us and we will continue to sell shares up to the
maximum amount of 10,000,000 shares.
Upon the effectiveness of this prospectus:
The selling security holders may offer to resell shares of our common stock
being registered in this prospectus for a price per share of $0.50 and a total
amount of $500,000 (that may fluctuate) until the securities are quoted on the
OTC Bulletin Board (or a national exchange) and thereafter from time to time at
prevailing market prices at the time of sale.
The securities offered in this prospectus involve a high degree of risk. See
"risk factors" beginning on page 5 of this prospectus to read about factors you
should consider before buying shares of our common stock.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined whether
this prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.
The date of this prospectus is December 21, 2006
The following table of contents has been designed to help you find information
contained in this prospectus. We encourage you to read the entire prospectus.
TABLE OF CONTENTS
PROSPECTUS SUMMARY 3
RISK FACTORS 5
FORWARD-LOOKING STATEMENTS 12
THE OFFERING 12
USE OF PROCEEDS 13
DETERMINATION OF OFFERING PRICE 13
SELLING SECURITY HOLDERS 13
PLAN OF DISTRIBUTION 16
LEGAL PROCEEDINGS 22
DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS
AND CONTROL PERSONS 22
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT 24
DESCRIPTION OF SECURITIES 25
EXPERTS 27
INTEREST OF NAMED EXPERTS AND COUNSEL 27
DISCLOSURE OF COMMISSION POSITION OF
INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 27
ORGANIZATION WITHIN THE LAST FIVE YEARS 28
DESCRIPTION OF BUSINESS 30
DESCRIPTION OF PROPERTY 37
MANAGEMENT'S DISCUSSION AND ANALYSIS
OR PLAN OR OPERATION 37
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 38
MARKET FOR COMMON EQUITY AND RELATED
STOCKHOLDER MATTERS 40
EXECUTIVE COMPENSATION 41
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE 43
FINANCIAL STATEMENTS 44
As used in this prospectus, the terms "we", "us", "our" and "Mazal" means Mazal
Plant Pharmaceuticals, Inc., a Nevada corporation, unless otherwise indicated.
"Delaware Mazal" refers to our subsidiary, Mazal Plant Pharmaceuticals, Inc., a
private Delaware corporation.
PROSPECTUS SUMMARY
General
Although we are now a Nevada corporation, we were originally organized pursuant
to the laws of the State of Colorado on April 9, 1998 under the name "Akid
Corporation". Our only activity prior to June 6, 2005 had been attempts to
locate and negotiate with a business entity for the merger of that target
company into us. Our operations prior to June 6, 2005 consisted solely of
seeking merger or acquisition candidates, and we had no business operations or
revenues. Our principal executive office is located at 43 West 33rd Street,
Suite 405, New York, NY 10001, and our telephone number is (212) 695-3334.
On June 6, 2005, we underwent a change in control and substantially shifted the
focus of our business. On June 6, 2005, a majority of our common stock was
acquired by Advanced Plant Pharmaceuticals, Inc., a Delaware corporation,
pursuant to the Share Exchange Agreement, dated May 2005, among Advanced Plant
Pharmaceuticals, Inc., Akid Corporation, and James B. Wiegand, who was one of
our principals at the time. Pursuant to the Share Exchange Agreement, we agreed
to issue to Advanced Plant Pharmaceuticals, Inc. 20,000,000 shares of Akid
Corporation common stock which represented 94.21 % of Akid Corporation issued
and outstanding common stock. In exchange, Advanced Plant Pharmaceuticals, Inc.
transferred to us 7,000,000 shares of the common stock of Mazal Plant
Pharmaceuticals, Inc., a Delaware corporation (the "Delaware Mazal"), which
represented 69% of the issued and outstanding shares of the Delaware Mazal. For
accounting purposes, such transaction is characterized as a reverse merger
between the Delaware Mazal and Mazal.
On June 6, 2005, we entered into a stock purchase agreement for the purchase the
remaining 3,130,000 shares of the issued and outstanding shares of common stock
of the Delaware Mazal, which represented 31% of the issued and outstanding
shares of the Delaware Mazal, from Gerry Gruenbaum, Barry Ginsburg, Avraham
Harris, Chaim Lieberman, David Lieberman, Sam Berkowitz and Mechael Kanovsky
each an individual stockholder of Delaware Mazal, in exchange for 6,180,000
shares of our common stock. Each of Gerry Gruenbaum and Barry Ginsburg were
provided with one share of our stock for each share of the Delaware Mazal held
by them. The other stockholders of the Delaware Mazal swapped each of their
Delaware Mazal shares in consideration for two of our shares.
As a result of the closing of the Share Exchange Agreement, Advanced Plant
Pharmaceuticals now holds a majority of the issued and outstanding shares of our
common stock, and we hold all of the issued and outstanding shares of common
stock of the Delaware Mazal. James B. Wiegand, who had been serving as our sole
director and officer since April 1998, resigned from his positions with us on
June 6, 2005. On the same date as Mr. Wiegand's resignation, Mechael Kanovsky
was elected to serve as director and as Chief Executive Officer and Sam
Berkowitz was elected to serve as Secretary.
Prior to the merger the Delaware Mazal held the patent transferred by Advanced
Plant Pharmaceuticals and was engaged in the development, manufacture, and
distribution of plant-based pharmaceutical drugs for the treatment of various
human illnesses until such operations were transferred to us. Since such change
in control, we continue to engage in the development, manufacture, and
distribution of plant-based pharmaceutical drugs for the treatment of various
human illnesses. Our only product currently under development is MAHDL-01, a
plant based drug whose purpose is the improving of levels of cholesterol in the
bloodstream and the prevention of cardiovascular diseases associated with
improper cholesterol levels.
On April 8, 2005, the Delaware Mazal submitted to the FDA the Investigational
New Drug application (IND) for the Phase I/II clinical trials of MAHDL-01 (IND
#72,040). Mazal has not commenced Phase I/II clinical trials of MAHDL-01 and
such trials are dependent on the receipt of adequate financing.
On November 9, 2005, we changed our state of incorporation from Colorado to
Nevada by the merger of Akid Corporation with and into a wholly owned subsidiary
we formed pursuant to the laws of Nevada under the name Mazal Plant
Pharmaceuticals, Inc. As a result of such merger, our name was changed to Mazal
Plant Pharmaceuticals, Inc., which is identical to the company name of the
Delaware Mazal, in order to better reflect our business operations.
3
On November 17, 2005 Mazal negotiated and executed a letter of intent to enter
into a possible joint venture with Punzi Medical Center to conduct and
participate in Phase I/II and consult on obtaining FDA approval for Phase III
trials and participating in such Phase III trials. On July 30, 2006 we executed
an interim letter agreement with Dr. Veronica Motiram to conduct and participate
in Phase I/II trials.
In addition, Mazal is currently undergoing negotiations with additional medical
centers and clinical research organization (CROs) to monitor the Phase I/II
trials at the various medical centers.
Number of Shares Being Offered
The prospectus relates to:
o The sale by us to the public of up to 10,000,000 shares of common stock at a
price of $0.45 per share. We will offer the shares directly to the public
through our Chief Financial Officer. The Chief Financial Officer will not
receive any commissions in connection with the offer and sale of the shares
under this prospectus.
o The registration by certain of our selling security holders of up to 7,295,996
common shares comprised of the following: (a) up to 6,295,996 shares of our
common stock that were issued in various transactions exempt from registration
under the Securities Act of 1933 and (b) up to 1,000,000 shares of our common
stock which may be issued upon exercise of a warrant that was issued in a
transaction exempt from registration. The selling security holders plan to sell
these shares at a price of $0.55 (that may fluctuate) until the securities are
quoted on the OTC Bulletin Board (or a national exchange) and thereafter from
time to time in market transactions at prevailing market prices.
Number of Common Shares Outstanding
We have 39,975,000 shares of common stock outstanding as of August 27, 2006.
Use of Proceeds
We will receive proceeds from our sale of shares to the public under this
prospectus, however, we will not receive any of the proceeds from the sale of
the common shares being offered for sale by the selling security holders.
However, we will receive proceeds from the resale of the warrant if and to the
extent that the warrant is exercised. The proceeds we receive shall be used for
the payment of costs and expenses we expect to incur in the conduct of human
clinical trials of MAHDL-01 that must be conducted in order for MAHDL-01 to be
approved by the United States Food and Drug Administration and any remaining
amounts will be used as working capital.
Summary Financial Data
On June 6, 2005, we entered into a stock purchase agreement with Advanced Plant
Pharmaceuticals, Inc., a Delaware corporation, to acquire 7,000,000 shares of
the common stock of the Delaware Mazal, in exchange for 20,000,000 shares of our
common stock. On June 6, 2005, we entered into a stock purchase agreement for
the purchase of 3,130,000 shares of the outstanding shares of common stock of
the Delaware Mazal from Gerry Gruenbaum, Barry Ginsburg, Avraham Harris, Chaim
Lieberman, David Liebeman, Sam Berkowitz and Mechael Kanovsky each an individual
stockholder of Delaware Mazal, in exchange for 6,180,000 shares of our common
stock. Each of Gerry Gruenbaum and Barry Ginsburg were provided with one share
of our stock for each share of Delaware Mazal held by them. The other
stockholders of Delaware Mazal swapped each of their Delaware Mazal shares in
consideration for two of our shares. In connection with the merger with and into
a wholly owned subsidiary we formed pursuant to the laws of Nevada under the
name Mazal Plant Pharmaceuticals, Inc, the Delaware Mazal became our wholly
owned subsidiary. Prior to the merger, we were a non-operating "shell"
corporation. Pursuant to Securities and Exchange Commission rules, the merger of
a private operating company into a non-operating public shell corporation, with
nominal net assets is considered a capital transaction. At the time of the
merger, our officers and directors resigned and were replaced with the officers
and directors of the Delaware Mazal. For Financial Statement presentation, the
merger has been reflected in the Financial Statements as though it occurred on
December 31, 2004. The historical statements prior to December 31, 2004 are
those of the Delaware Mazal. Since the merger is a recapitalization and not a
business combination, pro forma information is not presented.
4
The following summary financial information for the period May 18, 2004
(inception) to December 31, 2006 includes balance sheet and statement of
operations data from the audited annual consolidated financial statements from
December 31, 2004 and the audited annual consolidated financial statements from
December 31, 2005 and the unaudited financial statements for the period January
1, 2006 to March 31, 2006 and for the period of April 1, 2006 to June 30, 2006.
Mazal Plant Pharmaceuticals, Inc.
- -----------------------------------------------------------------------------------------------------------------------------
For the Period May 18, For the Period January For the Period January For the Period April
2004 (inception) to 1, 2005 to December 1, 2006 (inception) to 1, 2006 to
December 31, 2004 31, 2005 March 31, 2006 June 30, 2006
- ------------------------------------------------------------------------------------------------------------------------------
Statement of
Operations Data
- ------------------------------------------------------------------------------------------------------------------------------
Net Sales $- $- $- $-
- ------------------------------------------------------------------------------------------------------------------------------
Costs and Expenses 13,778 4,349,672 510,344 109,935
- ------------------------------------------------------------------------------------------------------------------------------
Net Loss (13,778) (4,349,672) (510,344) (109,935)
- ------------------------------------------------------------------------------------------------------------------------------
Net Loss per share $(0.01) $(0.14) $(0.01) $(0.01)
- ------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------
Balance Sheet Data
- ------------------------------------------------------------------------------------------------------------------------------
Total Assets 50,700 100,004 116,709 76,848
- ------------------------------------------------------------------------------------------------------------------------------
Total Current Liabilities 63,465 178,304 381,353 306,427
- ------------------------------------------------------------------------------------------------------------------------------
Total Stockholders' (12,765) (78,300) (264,644) (229,579)
Deficit
- ------------------------------------------------------------------------------------------------------------------------------
Total Liabilities and $50,700 $100,004 $116,709 $76,848
Stockholders' Deficit
- ------------------------------------------------------------------------------------------------------------------------------
RISK FACTORS
An investment in our common shares must be considered highly speculative,
generally because of the nature of our business and the general stage of its
development. In addition to the usual risks associated with investment in a
business, potential investors should carefully review the following factors
together with the other information contained in this prospectus before making
an investment decision. The risks described below are the material risks facing
us. If any of the following risks actually occur, our business, financial
condition and operating results could be materially affected.
5
GOING CONCERN
OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS HAVE EXPRESSED SUBSTANTIAL DOUBT
ABOUT OUR ABILITY TO CONTINUE AS A GOING CONCERN AND IF WE FAIL TO PRODUCE
REVENUES WE MAY FAIL IN OUR BUSINESS, CEASE OPERATIONS, AND YOU MAY LOSE YOUR
ENTIRE INVESTMENT.
Our independent registered public accountants have audited our financial data
and information and rendered a statement that they have substantial doubt about
our ability to continue as a going concern for the following reasons:
o we have limited financial resources and we have an accumulated
deficit of $4,985,389 since inception until June 30, 2006;
o we have negative working capital of $293,263 as of June 30,2006;
o we have a stockholders` deficit of $229,579 as of June 30, 2005;
and
o our ability to obtain capital and operate successfully is uncertain.
RISKS RELATED TO THIS OFFERING
THE SALE OF SHARES UNDER THIS PROSPECTUS AND THE ISSUANCE OF ADDITIONAL SHARES
THAT WE HAVE ALREADY AUTHORIZED MAY CAUSE OUR STOCK PRICE TO DROP, WILL DILUTE
THE PERCENTAGE OF COMMON STOCK OWNED BY EACH OF OUR EXISTING STOCKHOLDERS AND
MAY MAKE IT DIFFICULT FOR US TO RAISE FUNDS FROM THE SALE OF EQUITY SECURITIES.
We have 39,975,000 shares of common stock outstanding as of August 27, 2006. The
issuance of additional shares authorized by us
o May cause our stock price to drop significantly below the offering
price of stock under this prospectus;
o Will dilute the percentage ownership of our stockholders by
twenty (20%) percent.
o Any significant decrease in the price of our common stock could
encourage short sales by the selling stockholders or others. Any
such short sales could cause the market price of our common stock to
decrease even further.
The issuance of additional shares authorized by us in the public market could
materially impair our ability to raise capital through future offerings of our
common stock because of low stock price and further dilution of existing
stockholders. If we are unable to raise capital through offering of our common
stock, we will be unable to finance future clinical and pre-clinical activities,
which would have a serious negative impact on the future prospects of our
business.
6
RISKS RELATED TO OUR BUSINESS
SINCE WE ARE AT AN EARLY STAGE OF DEVELOPMENT, WE HAVE NOT COMPLETED THE
DEVELOPMENT OF ANY PRODUCT AND WE HAVE NOT BEGUN TO MARKET OR GENERATE REVENUES.
WE DO NOT ANTICIPATE GENERATING ANY REVENUE IN THE FORESEEABLE FUTURE. IF WE ARE
UNSUCCESSFUL IN COMPLETING THE DEVELOPING AND MARKETING OF OUR PRODUCTS, OUR
SECURITIES WILL BE WORTHLESS.
We are at an early stage of development. Our operations to date have consisted
primarily of developing and testing our MAHDL-01 product. MAHDL-01 will require
significant additional clinical testing and investment prior to
commercialization. A commitment of substantial resources by us and/or future
collaborative partners to conduct time-consuming research and clinical trials
will be required if we are to complete the development of MAHDL-01. We do not
know if we will be able to complete these tasks. We do not expect MAHDL-01 to be
commercially available for several years. Accordingly, we do not know if and
when we will generate revenues from MAHDL-01. Because of these uncertainties, we
might never generate enough revenue to allow shareholders to recoup and profit
from their investment.
SINCE WE HAVE A HISTORY OF OPERATING LOSSES AND EXPECT EXPENSES AND LOSSES TO
INCREASE IN THE NEAR TERM, WE DO NOT KNOW IF WE WILL EVER BECOME PROFITABLE OR
THAT OUR INVESTORS WILL EVER RECOUP OR PROFIT FROM THEIR INVESTMENT IN OUR
SHARES.
From the date of incorporation to June 30, 2006, our accumulated deficit is
$4,985,389. Since inception we have earned no revenues from the sale of any of
our product candidates. We expect expenses and losses to increase in the near
term as we fund research and development and general and administrative
expenses. We expect to continue to incur substantial operating losses unless and
until product sales and royalty payments generate sufficient revenues to fund
continuing operations. As a result, investors might never recoup their
investment or profit from their investment in our shares.
SINCE OUR SUCCESS IS DEPENDENT ON THE SUCCESSFUL COMPLETION OF CLINICAL TRIALS,
REGULATORY APPROVAL AND INTRODUCTION OF OUR PRODUCTS INTO THE MARKET, AND SINCE
WE HAVE COMPLETED NONE OF THE TASKS AT THIS TIME, WE DO NOT KNOW IF WE WILL BE
ABLE TO COMPLETE THEM.
The actual timing of these events can vary dramatically due to factors such as
delays or failures in our clinical trials, the uncertainties inherent in the
regulatory approval process, and the inability to establish on favorable terms
the collaborative partnerships that we plan to use for the completion of our
clinical trials and the marketing and manufacturing of our product candidates.
We might not be able to complete the clinical trials involving MAHDL-01, to make
the necessary regulatory submissions, or to gain regulatory approvals necessary
for marketing our products. Our failure to achieve these objectives will mean
that investors will not be able to recoup their investment or to receive a
profit on their investment.
7
WE WILL CONTINUE TO REQUIRE SUBSTANTIAL ADDITIONAL FUNDS FOR FURTHER RESEARCH
AND DEVELOPMENT, PLANNED CLINICAL TRIALS AND REGULATORY APPROVALS. WE MIGHT NOT
BE ABLE TO OBTAIN ADDITIONAL FUNDING ON ACCEPTABLE TERMS, IF AT ALL. WITHOUT
ADDITIONAL FUNDING, WE WILL FAIL.
From the date of incorporation to June 30, 2006, our negative working capital is
$293,263. We will require substantial additional funds for further research and
development, the conduct of our Phase I/II clinical trials for MAHDL-01 and
regulatory approvals. Our planned cash requirements may vary materially in
response to a number of factors, including research and development on our
products, the progress of our Phase I/II clinical trials and the results of
those trials, changes in any aspect of the regulatory process, and delays in
obtaining regulatory approvals. We may seek further funding through public or
private equity or debt financings, collaborative arrangements with
pharmaceutical companies or from other sources. Further equity financings may
substantially dilute shareholders' investment in our shares. If we cannot obtain
the required additional funding, then investors will not be able to recoup their
investment or to profit from their investment.
SINCE WE RELY SUBSTANTIALLY ON OUR ABILITY TO PATENT OUR INTELLECTUAL PROPERTY
OR MAINTAIN OUR PROPRIETARY INFORMATION AS TRADE SECRETS IN DEVELOPING OUR
PRODUCTS, OUR SUCCESS WILL DEPEND ON OUR ABILITY TO OBTAIN PATENTS, MAINTAIN
TRADE SECRET PROTECTION AND OPERATE WITHOUT INFRINGING ON THE PROPRIETARY RIGHTS
OF THIRD PARTIES OR PREVENTING THIRD PARTIES FROM CIRCUMVENTING OUR RIGHTS. AS
DESCRIBED BELOW, THERE IS CONSIDERABLE UNCERTAINTY ABOUT OUR INTELLECTUAL
PROPERTY RIGHTS. IF WE ARE UNSUCCESSFUL IN ESTABLISHING THE VALIDITY OF OUR
INTELLECTUAL PROPERTY RIGHTS, WE WILL LIKELY FAIL AS A COMPANY AND OUR
SECURITIES WILL BE WORTHLESS.
We have secured a U.S. patent in a version of MAHDL-01 known as Drug Formulation
1. Such patent will expire in 2013. In March 2005, we filed a U.S. patent
application for another version of MAHDL-01, and such application is still
pending. We also plan to file foreign patent applications. These steps we have
taken and will continue to take to protect our intellectual property may not
prevent the misappropriation of our proprietary information and technologies.
The patent positions of biotechnology and pharmaceutical companies can be highly
uncertain and involve complex legal and factual questions. We are uncertain
whether:
o any of our patent applications will result in the issuance of
patents;
o we will develop additional proprietary products that are patentable;
o the patent already issued to us will provide us with any competitive
advantages;
o we will be challenged by third parties on the validity of our
patents;
o the patents of others will impede our ability to do business;
o third parties will be able to circumvent our patents;
o third parties will independently develop similar products that will
not infringe our products;
o third parties will duplicate any of our products not covered by a
patent; or
o third parties will design around our patents.
8
Since patent applications in the United States are maintained in secrecy until
the patent is issued or foreign counterparts, if any, published and, since
publication of discoveries in the scientific or patent literature often lag
behind actual discoveries, we do not know if there are currently pending
applications that would result in issued patents that would interfere with
MAHDL-01. Moreover, we might have to participate in interference proceedings
declared by the U.S. Patent and Trademark Office to determine priority of
invention, which could result in substantial cost to us, even if the eventual
outcome is favorable to us.
Much of our know-how and technology might not be patentable. To protect our
rights, we require employees, consultants, advisors and collaborators to enter
into confidentiality agreements. However, these agreements might not provide
meaningful protection for trade secrets, know-how or other proprietary
information in the event of any unauthorized use or disclosure.
WE INTEND TO ENTER INTO VARIOUS ARRANGEMENTS WITH CORPORATE AND ACADEMIC
COLLABORATORS, LICENSORS, LICENSEES AND OTHERS FOR THE RESEARCH, DEVELOPMENT,
CLINICAL TESTING, MANUFACTURING, MARKETING AND COMMERCIALIZATION OF MAHDL-01 AND
MAZAL WILL SUFFER FINANCIALLY IF SUCH THIRD PARTIES DO NOT FULFILL THEIR
CONTRACTUAL OBLIGATIONS.
We intend to enter into agreements to develop and commercialize MAHDL-01. We
might not be able to establish collaborations on favorable terms, if at all, or
that future collaborative arrangements will be successful. In addition, third
party arrangements may require us to grant certain rights to third parties,
including exclusive marketing rights to one or more products, or may have other
terms that are burdensome to us.
These third party arrangements may place responsibility on these third parties
to conduct Phase III clinical trials, to prepare and submit applications for
regulatory approval, or to market, sell and support product commercialization.
These third parties might not fulfill their obligations in a manner which
maximizes our revenues. These arrangements may also require us to transfer
certain material rights or issue equity securities to corporate investors,
licensees and others. If we license or sublicense our commercial rights to
others we might realize reduced product revenue compared to our direct
commercial exploitation. Moreover, we might not derive any revenue or profit
from these arrangements.
We have no direct experience in marketing, sales or distribution, and we do not
intend to develop a sales and marketing infrastructure to commercialize
pharmaceutical products.
We have no direct experience in marketing, sales or distribution,
and we do not intend to develop a sales and marketing infrastructure to
commercialize pharmaceutical products. If we develop products eligible for
commercial sales, we intend to rely on third parties such as licensees,
collaborators, joint venture partners or independent distributors to market and
sell these products. We might not be able to obtain access to a marketing and
sales force with sufficient technical expertise and distribution capability. We
also will not be able to control the resources and effort that a third party
will devote to marketing our product candidates. If we are unable to develop and
maintain relationships with third parties with the necessary marketing and sales
force, we may fail to gain market acceptance of our product candidates, and our
revenues could be impaired.
9
Our key personnel would be difficult to replace.
We believe that our success will depend on the continued employment of our
senior management team and technical personnel. If one or more members of our
senior management team were unable or unwilling to continue in their present
positions, our business would suffer.
RISKS RELATED TO OUR INDUSTRY
BECAUSE THE MANUFACTURE AND MARKETING OF HUMAN PHARMACEUTICAL PRODUCTS REQUIRES
THE APPROVAL OF THE FOOD AND DRUG ADMINISTRATION IN THE UNITED STATES AND
SIMILAR AGENCIES IN OTHER COUNTRIES, AND SINCE WE DO NOT YET HAVE SUCH APPROVAL,
SHAREHOLDERS ARE AT RISK THAT WE WILL BE UNABLE TO SUCCESSFULLY DEVELOP AND
MARKET OUR PRODUCTS. WE HAVE NOT YET ESTABLISHED THAT OUR PRODUCTS WILL BE SAFE
AND EFFECTIVE THROUGH CLINICAL TRIALS.
The manufacture and marketing of human pharmaceutical products in the United
States and other countries require the approval from the United States Food and
Drug Administration and other similar foreign regulatory agencies. The process
that our pharmaceutical product candidates must undergo to obtain these
approvals includes preclinical testing and clinical trials to demonstrate safety
and efficacy. For example, we are about to commence Phase I/II clinical trials
for MAHDL-01. Such process is expensive and time consuming. Investors are at
risk that we will be unable to successfully develop future products, prove
safety and effectiveness in clinical trials, or receive applicable regulatory
approvals.
REGULATORY AUTHORITIES HAVE THE POWER TO WITHDRAW A PREVIOUSLY APPROVED PRODUCT
FROM THE MARKET UPON A CHANGE IN REGULATIONS OR UPON RECEIPT OF NEWLY DISCOVERED
INFORMATION AND/OR REQUIRE ADDITIONAL, AND POTENTIALLY EXPENSIVE, ADDITIONAL
TESTING. SINCE WE HAVE NO HISTORY WITH OUR PRODUCTS, WE MIGHT FACE SUCH NEWLY
DISCOVERED INFORMATION THAT COMES TO LIGHT AFTER INITIAL APPROVAL OF OUR
PRODUCTS.
Unanticipated changes in existing regulations or the adoption of new regulations
could adversely affect the development, manufacture and marketing of our
products. Since we have no operating history, ongoing government regulation
could cause unexpected delays and adversely impact our business in areas where
our inexperience might lead to failure in complying with applicable
requirements. Such failure to comply might also result in criminal prosecution,
civil penalties, recall or seizure of products, or partial or total suspension
of production. Any of these penalties could delay or prevent the promotion,
marketing or sale of our products. Furthermore, the laws, regulations, policies
or current administrative practices of any governmental body, organization or
regulatory agency in the United States or any other jurisdiction, might be
changed, or applied or interpreted in a manner which will fundamentally alter
the ability of us or our collaborative partners to develop, operate, export or
market the products or services which we may provide. We do not have lobbying or
other resources to affect the course of such changes. If such future changes
have an adverse impact on our products or their manufacture and marketing, the
likelihood of our success could be damaged.
10
IF OUR COMPETITORS SUCCEED IN DEVELOPING COMPETING PRODUCTS EARLIER THAN WE DO,
IN OBTAINING REGULATORY APPROVALS FOR SUCH PRODUCTS MORE RAPIDLY THAN WE DO, OR
IN DEVELOPING PRODUCTS THAT ARE MORE EFFECTIVE OR LESS EXPENSIVE THAN THE
PRODUCTS WE DEVELOP, WE WILL HAVE DIFFICULTY COMPETING WITH THEM.
Since our competitors keep this type of information confidential, we do not know
where they stand in developing competing products. As a result, we might be
using our resources to develop products that will face such competition from our
competitors and our products might not be successful in the marketplace. Our
future success depends on our ability to timely identify new market trends and
develop, introduce and support new and enhanced products on a successful and
timely basis. We might not be successful in developing or introducing to the
market our products. If we fail to develop and deploy new products on a
successful and timely basis, we will be non-competitive and unable to recoup the
research and development and other expenses we incur to develop and test new
product candidates.
EVEN IF MAHDL-01 IS APPROVED FOR SALE BY THE REGULATORY AUTHORITIES, WE HAVE NOT
YET DEMONSTRATED THAT WE WILL BE ABLE TO SELL THE PRODUCT AND THE PRODUCT MIGHT
NOT GAIN MARKET ACCEPTANCE AMONG PHYSICIANS, PATIENTS, HEALTHCARE PAYERS AND THE
MEDICAL COMMUNITY.
The degree of market acceptance will depend on a number of factors, including:
o demonstration of the clinical efficacy and safety of each product;
o cost-effectiveness;
o potential advantage over alternative treatment methods;
o the effectiveness of marketing and distribution support for each
product; and
o reimbursement policies of government and third party payers.
If our product candidates do not achieve significant market acceptance, our
business and financial condition will be materially adversely affected.
OUR SUCCESS MAY DEPEND IN PART ON THE EXTENT TO WHICH REIMBURSEMENT FOR THE COST
OF OUR PRODUCTS WILL BE AVAILABLE FROM GOVERNMENT HEALTH ADMINISTRATION
AUTHORITIES, PRIVATE HEALTH COVERAGE INSURERS AND OTHER ORGANIZATIONS, SINCE
POTENTIAL CUSTOMERS MIGHT NOT USE OUR PRODUCTS IF SUCH REIMBURSEMENT IS NOT
AVAILABLE.
At the present time, we have not established that such governmental authorities
or non-governmental providers will reimburse physicians and patients for the use
of our products. Recently, the prices of medical products and services have
increasingly been examined and challenged by third parties and consumers of such
products and services. We anticipate that new federal or state legislation will
be proposed to attempt to provide broader and better health care and to manage
and contain costs. Since we have not yet established reimbursement coverage, we
face significant uncertainty as to the reimbursement status of newly approved
health-care products and whether third party reimbursement will be available at
price levels sufficient for us to realize our desired returns.
11
SINCE WE WILL BE ADMINISTERING OUR PRODUCTS IN HUMAN CLINICAL TRIALS AND
THEREAFTER TO PATIENTS, WE WILL BE SUBJECT TO POTENTIAL PRODUCT LIABILITY CLAIMS
WHICH ARE INHERENT IN THE TESTING, MANUFACTURING, MARKETING AND SALE OF
THERAPEUTIC PRODUCTS AND THE PURCHASE OF LIABILITY INSURANCE IS EXPENSIVE AND
DIFFICULT TO OBTAIN.
Our clinical studies will include trials on humans. For example, the Phase I/II
trials create a risk of liability for serious side effects to participants
resulting from an adverse reaction to the products being tested or resulting
from negligence or misconduct and the associated adverse publicity. We manage
our liability risks by trying to follow proper protocols and through product
liability insurance. We intend to purchase liability insurance for clinical
trials at the time we begin such trials. Such insurance is expensive and
difficult to obtain. In the future, insurance coverage might not be available to
us on acceptable terms, if at all. If we are unable to obtain sufficient
insurance coverage on reasonable terms or to otherwise protect against potential
product liability claims we might not be able to commercialize our products. If
we face a future product liability claim or a product withdrawal, we will suffer
a material adverse effect on our financial condition.
FORWARD-LOOKING STATEMENTS
This prospectus contains forward-looking statements which relate to future
events or our future financial performance. In some cases, you can identify
forward-looking statements by terminology such as "may", "should", "expects",
"plans", "anticipates", "believes", "estimates", "predicts", "potential" or
"continue" or the negative of these terms or other comparable terminology. These
statements are only predictions and involve known and unknown risks,
uncertainties and other factors, including the risks in the section entitled
"Risk Factors" on pages 4 to 12, that may cause our or our industry's actual
results, levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance or
achievements expressed or implied by these forward-looking statements.
While these forward-looking statements, and any assumptions upon which they are
based, are made in good faith and reflect our current judgment regarding the
direction of our business, actual results will almost always vary, sometimes
materially, from any estimates, predictions, projections, assumptions or other
future performance suggested herein. Except as required by applicable law,
including the securities laws of the United States, we do not intend to update
any of the forward-looking statements to conform these statements to actual
results.
THE OFFERING
We are offering for sale to the public up to 10,000,000 shares of common stock
at $0.45 per share. We will offer the shares directly to the public through our
Chief Financial Officer, Mr. Simcha Edell. Mr. Edell will not receive any
commissions in connection with the offer and sale of the shares by us under this
prospectus.
We also are registering for resale by certain of our selling security holders up
to 7,295,996 shares of common stock comprised of the following: (a) up to
6,295,996 shares of our common stock that were issued in various transactions
exempt from registration under the Securities Act of 1933 and (b) up to
1,000,000 shares of our common stock which may be issued upon exercise of
certain warrants that were issued in a transaction exempt from registration. The
selling security holders may sell their common shares from time to time at
prevailing market prices at the time of sale.
12
USE OF PROCEEDS
The offering by Mazal has a minimum offering amount of $1,500,000. The net
proceeds available to us from the sale of the shares in this offering are
estimated to be approximately $4,425,000 if the maximum offering is sold, after
deducting offering expenses (estimated to be $75,000). We will not receive any
of the proceeds from the sale of the common shares to be sold from time to time
by the selling security holders. However, we will receive gross proceeds of up
to $500,000 from the exercise of the warrants if and to the extent that any of
the warrants are exercised. Depending on the timing of such proceeds, and the
amounts received from this offering, such proceeds will be used for general
working capital purposes.
We plan to use the net proceeds that we receive from the sale of our shares to
the public at various funding levels as percentages of the maximum offering for
the following purposes as outlined below:
PERCENT OF NET PROCEEDS RECEIVED (1)
33% (3) 66% (4) 100% (5)
--------- --------- ---------
$ $ $ --
Phase I/II clinical trials (2) 950,000 2,000,000 2,350,000
Research and development costs 0 125,000 275,000
Professional services fees 50,000 100,000 150,000
Working capital (6) 425,000 700,000 900,000
Reserve for new business Acquisitions 0 0 750,000
Offering expenses 75,000 75,000 75,000
--------- --------- ---------
TOTAL 1,500,000 3.000,000 4,500,000
========= ========= =========
(1) This table includes estimated offering expenses of $75,000.
(2) Depending upon the success, if any, of our offering, (i) if we raise at
least $1.5M a majority of the funds that we raise will be utilized to finance
the main segment of the Phase I/II clinical trials of MAHDL-01; in order to
perform the trials after reaching the first funding level of $1.5M, Mazal will
only conduct two of the four arms in order to provide the minimal amount of
statistically significant data necessary in order to continue the FDA approval
process to Phase III; If we raise $3.0M, $2.0M of such amount will be utilized
to finance the full four arm clinical study that Mazal intends to conduct. If we
raise $4.5M, an additional $350,000 will be utilized in order to finance the use
of a first tier CRO for their full four arm clinical study.
(3) The remaining amount of $550,000 not used for the clinical studies described
in footnote (2) will be utilized to maintain our general existence, pay offering
expenses and comply with our public reporting obligations.
(4) The remaining $1M not used for the clinical studies at this stage will be
utilized to undertake research and development work and maintain our general
existence and comply with its public reporting obligations.
(5) The remaining $2.15M not used for the clinical studies at this stage will be
utilized to undertake research and development work and maintain our general
existence and comply with its public reporting obligations and to reserve funds
for any potential new business acquisitions.
(6) The following is the intended breakdown of the working capital, at three
different funding levels:
WORKING CAPITAL 33% 67% 100%
- --------------------- -------- -------- --------
Current liabilities $100,000 $200,000 $200,000
salaries and related $250,000 $300,000 $360,000
Rental/utilities $ 35,000 $ 35,000 $ 40,000
Travel & IR $ 20,000 $ 65,000 $100,000
G&A, Misc. $ 20,000 $100,000 $200,000
Total working capital $425,000 $700,000 $900,000
DETERMINATION OF OFFERING PRICE
The offering price for the common stock to be sold in this offering has been
determined by our management. The price bears no relation to current income,
revenue or other objective financial data. The factors used by our management to
determine the offering price include the market potential for our products and
the growing potential of foreign markets for our products.
SELLING SECURITY HOLDERS
The selling security holders may offer and sell, from time to time, any or all
of the shares of common stock held by them and the common stock issuable to them
upon exercise of the warrants. Because the selling security holders may offer
all or only some portion of the 7,295,996 common shares to be registered, no
estimate can be given as to the amount or percentage of these common shares that
will be held by the selling security holders upon termination of the offering.
The following table sets forth certain information regarding the beneficial
ownership of common shares by the selling security holders as of August 27,
2006, and the number of common shares currently being registered. The number of
shares in the table represents the number of common shares being registered by
the selling security holder. To our knowledge none of the selling security
holders is a broker-dealer or an affiliate of a broker-dealer.
13
None of the selling security holders has any position, office or material
relationship with us, except for James B. Wiegand, who was our President and a
director from February 2003 until June 6, 2005, Sam Berkowitz, who is our
Secretary, Mechael Kanovsky, who is our Chief Executive Officer and a director,
Simcha Edell who is our Chief Financial Officer, Chaim Lieberman and David
Lieberman who are employees of Mazal. Except as otherwise, indicated, all
securities are owned directly.
- ---------------------------------------------------------------------------------------------------
NUMBER OF
SHARES
ISSUABLE COMMON COMMON
UPON SHARES SHARES
EXERCISE BEING BENEFICIALLY PERCENTAGE
COMMON SHARES OF ALL OFFERED OWNED OF CLASS
NAME OF SELLING BENEFICIALLY OWNED OF THE IN THE AFTER OWNED AFTER
SECURITY HOLDER BEFORE OFFERING (1) WARRANTS OFFERING (1) OFFERING (1) OFFERING (2)
- ---------------------------------------------------------------------------------------------------
Malcolm Jennings 2,355,444 0 1,835,444 520,000 1.3
- ---------------------------------------------------------------------------------------------------
Leonard Cohen 120,000 0 120,000 0 0
- ---------------------------------------------------------------------------------------------------
Debbie Gushlak 100,000 0 50,000 50,000 0.1
- ---------------------------------------------------------------------------------------------------
Ronnie Yacov 250,000 0 60,000 190,000 0.5
- ---------------------------------------------------------------------------------------------------
James B. Wiegand 625,000 0 50,000 575,000 1.4
- ---------------------------------------------------------------------------------------------------
Max Gould 625,000 0 50,000 575,000 1.4
- ---------------------------------------------------------------------------------------------------
Corporate Management
Services(8) 250,000 25,000 225,000 0.6
- ---------------------------------------------------------------------------------------------------
Chaim Lieberman 2,300,000(3) 0 1,000,000 1,300,000 3.3
- ---------------------------------------------------------------------------------------------------
David Lieberman 1,800,000(4) 0 50,000 1,750,000 4.4
- ---------------------------------------------------------------------------------------------------
Sam Berkowitz 1,800,000(5) 0 50,000 1,750,000 4.4
- ---------------------------------------------------------------------------------------------------
Mechael Kanovsky 800,000(6) 0 50,000 750,000 1.9
- ---------------------------------------------------------------------------------------------------
Luc Verelst (7) 1,625,000 1,000,000 2,625,000 0 0
- ---------------------------------------------------------------------------------------------------
Simcha Edell (9) 75,000 0 75,000 0 0
- ---------------------------------------------------------------------------------------------------
Chris Birts (10) 302,104 302,104 0 0
- ---------------------------------------------------------------------------------------------------
Rene Brezinger (10) 80,000 0 80,000 0 0
- ---------------------------------------------------------------------------------------------------
Ray Dirks (10) 20,000 0 20,000 0 0
- ---------------------------------------------------------------------------------------------------
CEDE (11) 199,5000 0 0 0 0
- ---------------------------------------------------------------------------------------------------
Louk Jongen (10) 80,000 0 80,000 0 0
- ---------------------------------------------------------------------------------------------------
Lanier Inc (10) 100,000 0 100,000 0 0
- ---------------------------------------------------------------------------------------------------
Bernie Meier (10) 80,000 0 80,000 0 0
- ---------------------------------------------------------------------------------------------------
Peter Mullen (10) 88,420 88,420 0 0
- ---------------------------------------------------------------------------------------------------
Richard Robbins (10) 40,000 0 40,000 0 0
- ---------------------------------------------------------------------------------------------------
Nicholas Wace (10) 125,528 0 125,528 0 0
- ---------------------------------------------------------------------------------------------------
14
(1) The number of common shares listed as beneficially owned by such selling
security holder represents the number of common shares owned as of August 27,
2006. Assumes all of the common shares registered by the selling stockholders in
this prospectus are sold by the selling stockholders.
(2) Based on 39,975,000 shares of common stock outstanding as of August 27,
2006.
(3) Chaim J. Lieberman received 2,300,000 shares of our common stock in
consideration for his services rendered to our subsidiary, the Delaware Mazal,
pursuant to an Employment Agreement, dated December 10, 2004, as amended on
August 1, 2005, among Mr. Lieberman, us, and the Delaware Mazal.
(4) David Lieberman received 1,800,000 shares of our common stock in
consideration for his services rendered to our subsidiary, the Delaware Mazal,
pursuant to an Employment Agreement, dated December 10, 2004, as amended on
August 1, 2005, among Mr. Lieberman, us, and the Delaware Mazal.
(5) Mr. Berkowitz, our Secretary, received 1,800,000 shares of our common stock
pursuant to the Employment Agreement, dated December 10, 2004, as amended on
August 1, 2005, among Mr. Berkowitz, Mazal, and our subsidiary, the Delaware
Mazal, as compensation for his services rendered to the Delaware Mazal.
(6) Dr. Mechael Kanovsky, our Chief Executive Officer and a director, received
800,000 shares of our common stock in consideration for his services rendered to
our subsidiary, the Delaware Mazal, pursuant to an Employment Agreement, dated
December 10, 2004, as amended on August 1, 2005, among Dr. Kanovsky, us and the
Delaware Mazal.
(7) Mr. Luc Verelest received 1,200,000 shares of our common stock and warrants
to purchase 1,000,000 shares of our common stock at an exercise price of $0.50
in consideration for $300,000.
(8) George Andrews and Joan Andrews are the beneficial owners of Corporate
Management Services.
(9) Simcha Edell, our Chief Financial Officer, received 75,000 shares of our
common stock in consideration for his services rendered to our subsidiary, the
Delaware Mazal, pursuant to an Employment Agreement with Delaware Mazal, dated
November 9, 2005.
(10) These shares were transferred to the selling stockholder by Malcolm
Jennings.
(11) These shares were transferred to the selling stockholder by FirstSouthwest.
15
We may require the selling security holders to suspend the sales of the
securities registered by this prospectus upon the occurrence of any event that
makes any statement in this prospectus or the related registration statement
untrue in any material respect or that requires the changing of statements in
these documents in order to make statements in those documents not misleading.
We will file a post-effective amendment to this registration statement to
reflect any material changes to this prospectus.
PLAN OF DISTRIBUTION
CURRENT MARKET FOR OUR SHARES
Our shares are currently traded on the Pink Sheets under the Symbol: MZPP.PK and
are subject to the penny stock rules. Broker-dealers may be discouraged from
effecting transactions in our shares because they will be considered penny
stocks and will be subject to the penny stock rules. Rules 15g-1 through 15g-9
promulgated under the Securities Exchange Act of 1934, as amended, impose sales
practice and disclosure requirements on NASD brokers-dealers who make a market
in a "penny stock." A penny stock generally includes any non-NASDAQ equity
security that has a market price of less than $5.00 per share. Under the penny
stock regulations, a broker-dealer selling penny stock to anyone other than an
established customer or "accredited investor" (generally, an individual with net
worth in excess of $1,000,000 or an annual income exceeding $200,000, or
$300,000 together with his or her spouse) must make a special suitability
determination for the purchaser and must receive the purchaser's written consent
to the transaction prior to sale, unless the broker-dealer or the transactions
is otherwise exempt. In addition, the penny stock regulations require the
broker-dealer to deliver, prior to any transaction involving a penny stock, a
disclosure schedule prepared by the Commission relating to the penny stock
market, unless the broker-dealer or the transaction is otherwise exempt. A
broker-dealer is also required to disclose commissions payable to the
broker-dealer and the registered representative and current quotations for the
securities. Finally, a broker-dealer is required to send monthly statements
disclosing recent price information with respect to the penny stock held in a
customer's account and information with respect to the limited market in penny
stocks.
The additional sales practice and disclosure requirements imposed upon
brokers-dealers may discourage broker-dealers from effecting transactions in our
shares, which could severely limit the market liquidity of the shares and impede
the sale of our shares in the secondary market, assuming one develops.
We have filed a Form 15c211 for the purpose of listing our shares on the OTC
Bulletin Board, which is maintained by the National Association of Securities
Dealers. We can provide no assurances that our shares will be listed on the OTC
Bulletin Board. Irrespective of whether our shares are traded on the OTC
Bulleting Board a purchaser of our shares may not be able resell our shares, and
our shares will remain subject to the penny stock rules.
16
The offering by Mazal will be Sold by Our Chief Financial Officer.
We are offering up to a total of 10,000,000 shares of common stock as a
self-undertaken offering. The offering price is $0.45 per share.
Until a minimum of $1,500,000 is raised by us by selling our common stock
offered in this prospectus, all payments for shares will be deposited into an
escrow account at Bank Hapoalim, New York. If $1,500,000 is not raised in this
offering by us by selling our common stock offered, all payments deposited in
the escrow account will be promptly refunded in full, without interest and
without any deduction for expenses. If $1,500,000 is raised by us by selling our
common stock offered in this offering, all funds held in escrow will be released
to us and we will continue to sell shares up to the maximum amount of 10,000,000
shares.
The offering by us of our common stock will be for a period of 180 business days
from the effective date and we have the right to terminate the offering of our
common stock by us at any time, even before we have sold the 10,000,000 shares.
There are no specific events which might trigger our decision to terminate the
offering.
We cannot assure you that all or any of the shares offered by us under this
prospectus will be sold. No one has committed to purchase any of the shares
offered. Therefore, we may only sell a nominal amount of shares and receive
minimal proceeds from the offering. We reserve the right to withdraw or cancel
this offering by us and to accept or reject any subscription in whole or in
part, for any reason or for no reason. Subscriptions will be accepted or
rejected promptly. All monies from rejected subscriptions will be returned by us
to the subscriber, without interest or deductions.
After the minimum offering is met, the funds deposited in the escrow account
will be transferred into an account maintained by us and be immediately
available to us. After the minimum offering is met and the funds are transferred
from the escrow account to our account there are no investor protections for the
return of subscription funds.
Once we receive the purchase price for the shares from the escrow account our
transfer agent shall issue certificates for shares purchased from us pursuant to
this registration statement.
We will sell the shares in this offering through our Chief Financial Officer,
Mr. Simcha Edell. Mr. Edell will receive no commission from the sale of Mazal
shares by us nor will he register as a broker-dealer pursuant to Section 15 of
the Securities Exchange Act of 1934 in reliance upon Rule 3(a)4-1. Rule 3(a)4-1
sets forth those conditions under which a person associated with an issuer may
participate in the offering of the issuer's securities and not be deemed to be a
broker-dealer. Our chief financial officer satisfies the requirements of Rule
3(a)4-1 in that:
1. He is not subject to a statutory disqualification, as that term is
defined in Section 3(a)(39) of the Act, at the time of his
participation; and,
2. He is not being paid commissions or other remuneration based either
directly or indirectly on transactions in securities; and
17
3. He is not, at the time of his participation, an associated person of
a broker- dealer; and
4. Mr. Edell meets the conditions of Paragraph (a)(4)(ii) of Rule
3(a)4-1 of the Exchange Act, in that he (A) primarily performs, or
are intended primarily to perform at the end of the offering,
substantial duties for or on behalf of the issuer otherwise than in
connection with transactions in securities; and (B) is not a broker
or dealer, or an associated person of a broker or dealer, within the
preceding twelve (12) months; and (C) does not participate in
selling and offering of securities for any issuer more than once
every twelve (12) months other than in reliance on Paragraphs
(a)(4)(i) or (a)(4)(iii).
As long as we satisfy all of these conditions, we are comfortable that we will
be able to satisfy the requirements of Rule 3a4-1 of the Exchange Act
notwithstanding that a portion of the proceeds from this offering will be used
to pay out our current liabilities including the payment of accrued salaries to
our Chief Financial Officer.
As our Chief Financial Officer will sell the shares being offered pursuant to
this offering, Regulation M prohibits the company and its officers and directors
from certain types of trading activities during the time of distribution of our
securities. Specifically, Regulation M prohibits our officers and directors from
bidding for or purchasing any common stock or attempting to induce any other
person to purchase any common stock, until the distribution of our securities
pursuant to this offering has ended.
We intend to advertise and hold investment meetings in various states where the
offering will be registered. We will also distribute the prospectus to potential
investors at the meetings and to our friends and relatives who are interested in
us and a possible investment in the offering.
We intend to pay accrued officer and director salaries as offering proceeds are
raised. The use of proceeds to pay accrued salaries will not be linked in any
way to Chief Financial Officer success or failure in selling securities.
OFFERING PERIOD AND EXPIRATION DATE
This offering will commence on the effective date of this prospectus, as
determined by the Securities and Exchange Commission and continue for a period
of 180 business days.
Procedures for Subscribing
If you decide to subscribe for any shares in this offering, you must deliver a
check or certified funds for acceptance or rejection. There are no minimum share
purchase requirements for individual investors. All checks for subscriptions
must be made payable to "Mazal Plant Pharmaceuticals, Inc." All amounts received
shall be held in escrow until $1,500,000 shall be deposited into the escrow
account thereafter all funds provided as subscriptions will be immediately
deposited into our account and be available.
18
RIGHT TO REJECT SUBSCRIPTIONS
We maintain the right to accept or reject subscriptions in whole or in part, for
any reason or for no reason. All monies from rejected subscriptions will be
returned immediately by us to the subscriber, without interest or deductions.
Subscriptions for securities will be conditionally accepted or rejected within
48 hours of our having received them. Such acceptance shall be conditioned upon
our raising a minimum amount of $1,500,000.
SELLING STOCKHOLDERS DISTRIBUTION
The selling security holders may, from time to time, sell all or a portion of
the common shares on any market upon which the common shares may be listed or
quoted (currently the Pink Sheets). Such sales may be at prevailing market
prices at the time of sale. The common shares being registered for resale by
this prospectus may be sold by the selling security holders by one or more of
the following methods:
(a) an exchange distribution in accordance with the rules of the
applicable exchange;
(b) ordinary brokerage transactions and transactions in which the broker
solicits purchasers;
(c) privately negotiated transactions;
(d) market sales (both long and short to the extent permitted under the
federal securities laws);
(e) at the market to or through market makers or into an existing market
for the shares; and
(f) through transactions in options, swaps or other derivatives (whether
exchange listed or otherwise).
In the event of the transfer by any of the selling security holders of its
warrants or common shares to any pledgee, donee or other transferee, we will
amend this prospectus and the registration statement of which this prospectus
forms a part by the filing of a post-effective amendment in order to have the
pledgee, donee or other transferee in place of the selling security holder who
has transferred his, her or its shares.
In effecting resales, brokers and dealers engaged by the selling security
holders may arrange for other brokers or dealers to participate. Brokers or
dealers may receive commissions or discounts from a selling security holder or,
if any of the broker-dealers act as an agent for the purchaser of such shares,
from a purchaser in amounts to be negotiated which are not expected to exceed
those customary in the types of transactions involved. Broker-dealers may agree
with a selling security holder to sell a specified number of the common shares
at a stipulated price per share. Such an agreement may also require the
broker-dealer to purchase as principal any unsold common shares at the price
required to fulfill the broker-dealer commitment to the selling security holder
if such broker-dealer is unable to sell the shares on behalf of the selling
security holder. Broker-dealers who acquire common shares as principal may
thereafter resell the common shares from time to time in transactions which may
involve block transactions and sales to and through other broker-dealers,
including transactions of the nature described above. Such sales by a
broker-dealer could be at prices and on terms then prevailing at the time of
sale, at prices related to the then-current market price or in negotiated
transactions. In connection with such resales, the broker-dealer may pay to or
receive from the purchasers of the shares commissions as described above.
19
The selling security holders and any broker-dealers or agents that participate
with the selling security holders in the sale of the common shares may be deemed
to be "underwriters" within the meaning of the Securities Act in connection with
these sales. In that event, any commissions received by the broker-dealers or
agents and any profit on the resale of the common shares purchased by them may
be deemed to be underwriting commissions or discounts under the Securities Act.
From time to time, any of the selling security holders may pledge common shares
pursuant to the margin provisions of customer agreements with brokers. Upon a
default by a selling security holder, their broker may offer and sell the
pledged common shares from time to time. Upon a sale of the common shares, the
selling security holders intend to comply with the prospectus delivery
requirements under the Securities Act by delivering a prospectus to each
purchaser in the transaction. We intend to file any amendments or other
necessary documents in compliance with the Securities Act that may be required
in the event any of the selling security holders defaults under any customer
agreement with brokers.
To the extent required under the Securities Act, a post effective amendment to
this registration statement will be filed disclosing the name of any
broker-dealers, the number of common shares involved, the price at which the
common shares is to be sold, the commissions paid or discounts or concessions
allowed to such broker-dealers.
We and the selling security holders will be subject to applicable provisions of
the Exchange Act and the rules and regulations under it, including, without
limitation, Rule 10b-5 and, insofar as a selling security holder is a
distribution participant and we, under certain circumstances, may be a
distribution participant, under Regulation M. All of the foregoing may affect
the marketability of the common shares.
All expenses of the registration statement including, but not limited to, legal,
accounting, printing and mailing fees are and will be borne by us. Any
commissions, discounts or other fees payable to brokers or dealers in connection
with any sale of the common shares will be borne by the selling security
holders, the purchasers participating in such transaction, or both.
Any common shares covered by this prospectus which qualify for sale pursuant to
Rule 144 under the Securities Act, as amended, may be sold under Rule 144 rather
than pursuant to this prospectus.
20
BLUE SKY RESTRICTIONS ON RESALE
When a selling security holder wants to sell common shares under this
registration statement, the selling security holders will also need to comply
with state securities laws, also known as "Blue Sky laws," with regard to
secondary sales. Many states, for example, have an exemption for secondary
trading of securities registered under Section 12(g) of the Securities Exchange
Act of 1934 or for securities of issuers that publish continuous disclosure of
financial and non-financial information in a recognized securities manual, such
as Standard & Poor's. The broker for a selling security holder will be able to
advise a selling security holder which states our common shares is exempt from
registration with that state for secondary sales.
Any person who purchases common shares from a selling security holder under this
registration statement who then wants to sell such shares will also have to
comply with Blue Sky laws regarding secondary sales.
When the registration statement becomes effective, and a selling security holder
indicates in which state(s) he desires to sell his shares, we will be able to
identify whether it will need to register or will rely on an exemption there
from.
ADDITIONAL SEC AND NASD RESTRICTIONS
Because the market price of our common stock is less than $5.00 per share, our
common stock is classified as a "penny stock." SEC Rules impose additional sales
practice requirements on broker-dealers that recommend the purchase or sale of
penny stocks to persons other than those who qualify as an "established
customer" or an "accredited investor." This includes the requirement that a
broker-dealer must make a determination that investments in penny stocks are
suitable for the customer and must make special disclosures to the customer
concerning the risks of penny stocks. Application of the penny stock rules to
our common stock could adversely affect the market liquidity of the shares,
which in turn may affect the ability of holders of shares of our common stock to
resell the shares. As a result of the difficulty in selling our shares,
investors may not be able to liquidate their shareholdings in our company as
quickly as they might otherwise be able to do in more conventionally traded
securities and therefore you may lose all or a significant portion of your
investment in our company.
In addition to the "penny stock" rules described above, the NASD has adopted
rules that require that in recommending an investment to a customer, a
broker-dealer must have reasonable grounds for believing that the investment is
suitable for that customer. Prior to recommending speculative low priced
securities to their non-institutional customers, broker-dealers must make
reasonable efforts to obtain information about the customer's financial status,
tax status, investment objectives and other information. Under interpretations
of these rules, the NASD believes that there is a high probability that
speculative low priced securities will not be suitable for at least some
customers. The NASD requirements make it more difficult for broker-dealers to
recommend that their customers buy our common stock, which may have the effect
of reducing the level of trading activity in our common stock. As a result,
fewer broker-dealers may be willing to make a market in our common stock,
reducing a stockholder's ability to resell shares of our common stock
21
PENNY STOCK REGULATIONS
You should note that our common shares are a penny stock. The Securities and
Exchange Commission has adopted Rule 15g-9 which generally defines "penny stock"
to be any equity security that has a market price (as defined) less than $5.00
per share or an exercise price of less than $5.00 per share, subject to certain
exceptions. Our securities are covered by the penny stock rules, which impose
additional sales practice requirements on broker-dealers who sell to persons
other than established customers and "accredited investors". The term
"accredited investor" refers generally to institutions with assets in excess of
$5,000,000 or individuals with a net worth in excess of $1,000,000 or annual
income exceeding $200,000 or $300,000 jointly with their spouse. The penny stock
rules require a broker-dealer, prior to a transaction in a penny stock not
otherwise exempt from the rules, to deliver a standardized risk disclosure
document in a form prepared by the SEC that provides information about penny
stocks and the nature and level of risks in the penny stock market. The
broker-dealer also must provide the customer with current bid and offer
quotations for the penny stock, the compensation of the broker-dealer and its
salesperson in the transaction and monthly account statements showing the market
value of each penny stock held in the customer's account. The bid and offer
quotations, and the broker-dealer and salesperson compensation information, must
be given to the customer orally or in writing prior to effecting the transaction
and must be given to the customer in writing before or with the customer's
confirmation. In addition, the penny stock rules require that prior to a
transaction in a penny stock not otherwise exempt from these rules, the
broker-dealer must make a special written determination that the penny stock is
a suitable investment for the purchaser and receive the purchaser's written
agreement to the transaction. These disclosure requirements may have the effect
of reducing the level of trading activity in the secondary market for the stock
that is subject to these penny stock rules. Consequently, these penny stock
rules may affect the ability of broker-dealers to trade our securities. We
believe that the penny stock rules discourage investor interest in and limit the
marketability of our common shares.
LEGAL PROCEEDINGS
There is no litigation or regulatory proceeding pending or threatened by or
against us.
DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS
Our directors, executive officers and other significant employees, their ages,
positions held and duration each person has held that position, are as follows:
NAME POSITION AGE
Dr. Mechael Kanovsky Chief Executive Officer and Director 43
Simcha Edell Chief Financial Officer 51
Chaim J. Lieberman Significant Employee 45
David Lieberman Significant Employee 43
22
BUSINESS EXPERIENCE
The following is a brief account of the education and business experience of
each director, executive officer and key employee during at least the past five
years, indicating each person's principal occupation during the period, and the
name and principal business of the organization by which he was employed.
DR. MECHAEL KANOVSKY has served as our Chief Executive Officer and Director
since June 6, 2005. Since December 2004, he also has served as the part time
President and director of Amazon Biotech, Inc. a development stage company that
develops and markets pharmaceuticals for the HIV/ AIDS market. He obtained his
Ph.D. in Molecular Biology from Mount Sinai School of Medicine, New York. Dr.
Kanovsky worked as a research scientist with the Department of Pathology at the
Brooklyn VA Hospital and at State University of New York from 1999 until August
2002. Dr. Kanovsky worked as a senior cancer researcher in the biotech industry
for Gene Vectors Technologies, Israel from January 2003 until November 2003.
From January 2004 until November 2004, Dr. Kanovsky was a consultant for
Marantech Corp., a company in the business of researching, developing and
exploiting technological applications for various electron-jumping compounds. He
assisted Marantech in developing a cancer screening test.
MR. SIMCHA EDELL has been at Mazal from July 2005, and presently functions as
CFO. He is also serves as the part time CFO of Amazon Biotech, Inc. a
development stage company that develops and markets pharmaceuticals for the HIV/
AIDS market. From July 2003 until March 2005 he was CEO of Advanced Combat
Systems Ltd., an Israeli company developing homeland security products. He was
head of finance and business development in SightLine Technologies Inc., an
Israeli firm developing medical devices, from January 2001 to April 2003 Inc. He
obtained his B.Comm from the University of Toronto, and his MBA from York
University.
Mr. Chaim J. Lieberman has been an employee at Mazal from December 2004 to
present and he is also the part time employee of Amazon Biotech, Inc. a
development stage company that develops and markets pharmaceuticals for the HIV/
AIDS market. For the previous five years Mr. Lieberman served as a whole plants
pharmaceutical consultant to Advanced Plant Pharmaceuticals, Inc., a Delaware
corporation which developed and sells nutritional supplements.. His position at
Mazal is head of business development.
MR. DAVID LIEBERMAN has been an employee at Mazal from December 2004 to present.
For the previous five years Mr. Lieberman was the president of Advanced Plant
Pharmaceuticals, Inc., a Delaware corporation which developed and sells
nutritional supplements.
23
Until the change in control of Mazal on June 6, 2005, our sole director and
officer was James B. Wiegand. Mr. Wiegand resigned as a result of our change in
control, not because of any disagreement with us.
Each director and executive officer holds office until the next annual meeting
of shareholders or until his successor has been duly elected and qualified.
There are no family relationships among the persons described below.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table lists, as of August 27, 2006, the number of shares of our
common stock beneficially owned by (i) each person or entity known to us to be
the beneficial owner of more than 5% of the outstanding common stock; (ii) each
of our officers and directors; and (iii) all of our officers and directors as a
group. Information relating to beneficial ownership of common stock by our
principal stockholders and management is based upon information furnished by
each person using "beneficial ownership" concepts under the rules of the
Securities and Exchange Commission. Under these rules, a person is deemed to be
a beneficial owner of a security if that person has or shares voting power,
which includes the power to vote or direct the voting of the security, or
investment power, which includes the power to vote or direct the voting of the
security. The person is also deemed to be a beneficial owner of any security of
which that person has a right to acquire beneficial ownership within 60 days.
Under the Securities and Exchange Commission rules, more than one person may be
deemed to be a beneficial owner of the same securities, and a person may be
deemed to be a beneficial owner of securities as to which he or she may not have
any pecuniary beneficial interest. Except as noted below, each person has sole
voting and investment power.
The percentages below are calculated based on 39, 975,000 shares of common stock
which we have authorized for issuance. Unless otherwise indicated, the business
address of each such person is c/o Mazal Plant Pharmaceuticals, Inc., 43 West
33rd Street, New York, NY 10001.
- ------------------------------------------------------------------------------------------------
OFFICERS, DIRECTORS NUMBER BENEFICIAL
AND 5% STOCKHOLDERS OF SHARES OWNERSHIP (%)
- ------------------------------------------------------------------------------------------------
Advanced Plant Pharmaceuticals, Inc. 20,000,000(1)* 50.0%
- ------------------------------------------------------------------------------------------------
Malcolm Jennings 2,355,444 (6) 5.9%
- ------------------------------------------------------------------------------------------------
Sam Berkowitz 1,800,000(2)* 4.5%
- ------------------------------------------------------------------------------------------------
Mechael Kanovksy 800,000(3)* 2.0%
- ------------------------------------------------------------------------------------------------
Chaim J. Lieberman 2,300,000(4)* 5.8%
- ------------------------------------------------------------------------------------------------
David Lieberman 1,800,000(5)* 4.5%
- ------------------------------------------------------------------------------------------------
Simcha Edell 75,000 (7)* 0.2%
- ------------------------------------------------------------------------------------------------
All directors and executive officers 2,675,000* 6.7%
as a group (3 persons)
- ------------------------------------------------------------------------------------------------
(1) Pursuant to the Share Exchange Agreement, dated June 6, 2005, among Mazal,
Advanced Plant Pharmaceuticals, Inc., and James Wiegand, Advanced Plant
Pharmaceuticals, Inc. received a total of 20,000,000 shares of our common stock
as consideration for its sale to us of its 7,000,000 shares of Mazal Plant
Pharmaceuticals, Inc. The sole director of Advanced Plant Pharmaceuticals, Inc.
is David Lieberman, and the beneficial owners of the shares held by Advanced
Plant Pharmaceuticals, Inc. are Ezriel Silberberg, David Lieberman and Chaim J.
Lieberman.
24
(2) Mr. Berkowitz received 1,800,000 shares of our common stock pursuant to the
Employment Agreement, dated December 10, 2004, as amended on August 1, 2005,
among Mr. Berkowitz, Mazal, and our subsidiary, the Delaware Mazal, as
compensation for his services rendered to the Delaware Mazal.
(3) Dr. Kanovsky received shares of our common stock pursuant to the Employment
Agreement, dated December 10, 2004, as amended on August 1, 2005, among Dr.
Kanovsky, us, and our subsidiary, the Delaware Mazal. Pursuant to such
employment agreement, Dr. Kanovsky is employed by the Delaware Mazal and
received a total of 600,000 shares of our common stock. On December 19th, 2006,
our Board of Directors issued an additional 100,000 shares of our common stock
to Dr. Kanovsky as a performance bonus. On January 25th, 2006, our Board of
Directors issued an additional 100,000 shares of our common stock to Dr.
Kanovsky as a performance bonus in consideration for the acceptance of the IND
by the FDA.
(4) Chaim J. Lieberman received 2,300,000 shares of our common stock in
consideration for his services rendered to our subsidiary, the Delaware Mazal,
pursuant to an Employment Agreement, dated December 10, 2004, as amended on
August 1, 2005, among Mr. Lieberman, us, and the Delaware Mazal. Pursuant to
such employment agreement, Mr. Lieberman is also entitled to receive 500,000
shares of our common stock each additional time that the Delaware Mazal receives
an IND and 100,000 shares of our common stock each time that the Delaware Mazal
receives a patent.
(5) David Lieberman received 1,800,000 shares of our common stock in
consideration for his services rendered to our subsidiary, the Delaware Mazal,
pursuant to an Employment Agreement, dated December 10, 2004, as amended on
August 1, 2005, among Mr. Lieberman, us, and the Delaware Mazal.
(6) Malcolm Jennings's address is 1 Regent Street, London SW1Y4NS UK.
(7) Mr. Edell received 75,000 shares of our common stock in consideration for
his services rendered to our subsidiary, the Delaware Mazal, pursuant to an
Employment Agreement, dated November 9, 2005. Mr. Edell is entitled to an
additional 75,000 shares of our common stock at the end of his first year of
employment, as compensation for services rendered to Delaware Mazal. In
addition, Mr. Edell is entitled to the issuance of additional 75,000 shares of
our common stock upon our receipt of one million dollars in funding.
DESCRIPTION OF SECURITIES
Our authorized capital stock consists of 100,000,000 shares of common stock, no
par value and 1,000,000 shares of non-voting preferred stock, no par value. The
following statements relating to the capital stock are summaries and do not
purport to be complete.
25
COMMON STOCK
Our Articles of Incorporation authorizes the issuance of 100,000,000
shares of common stock, no par value, as of August 27, 2006, 39,975,000 shares
have been issued. Holders of shares of common stock are entitled to one vote for
each share on all matters to be voted on by the stockholders. Holders of common
stock do not have cumulative voting rights. Holders of common stock are entitled
to share ratably in dividends, if any, as may be declared from time to time by
the Board of Directors in its discretion from funds legally available therefor.
In the event of a liquidation, dissolution or winding up of Mazal, the holders
of common stock are entitled to share pro rata all assets remaining after
payment in full of all liabilities.
Holders of common stock have no preemptive rights to purchase our common
stock. There are no conversion or redemption rights or sinking fund provisions
with respect to our common stock.
PREFERRED STOCK
Our Articles of Incorporation authorizes the issuance of 1,000,000 shares
of non-voting preferred stock, no par value, of which no shares have been
issued. The Board of Directors is authorized to provide for the issuance of
shares of preferred stock in series and, by filing a certificate pursuant to the
applicable law of Nevada, to establish from time to time the number of shares to
be included in each such series, and to fix the designation, powers, preferences
and rights of the shares of each such series and the qualifications, limitations
or restrictions thereof without any further vote or action by the shareholder.
Any shares of preferred stock so issued would have priority over the common
stock with respect to dividend or liquidation rights. Any future issuance of
preferred stock may have the effect of delaying, deferring or preventing a
change in control of us without further action by the shareholder and may
adversely affect the voting and other rights of the holders of common stock. At
present, we have no plans to issue any preferred stock nor adopt any series,
preferences or other classification of preferred stock.
The issuance of shares of preferred stock, or the issuance of rights to
purchase such shares, could be used to discourage an unsolicited acquisition
proposal. For instance, the issuance of a series of preferred stock might impede
a business combination by including class voting rights that would enable the
holder to block such a transaction, or facilitate a business combination by
including voting rights that would provide a required percentage vote of the
stockholders. In addition, under certain circumstances, the issuance of
preferred stock could adversely affect the voting power of the holders of the
common stock. Although the Board of Directors is required to make any
determination to issue such stock based on its judgment as to the best interests
of our stockholders, the Board of Directors could act in a manner that would
discourage an acquisition attempt or other transaction that some, or a majority,
of the stockholders might believe to be in their best interests or in which
stockholders might receive a premium for their stock over the then market price
of such stock. The Board of Directors does not at present intend to seek
stockholder approval prior to any issuance of currently authorized stock, unless
otherwise required by law or stock exchange rules. We have no present plans to
issue any preferred stock.
26
WARRANTS
On October 31, 2005, as part of a private placement transaction, we
granted to Mr. Luc Verelst, one of our current investors, a warrant to purchase
1,000,000 unregistered shares of our common stock at $0.50 per share. This
warrant is exercisable by Mr. Verelst until October 30, 2008. If Mr. Verelst's
exercises the warrant we shall receive $500,000 in gross proceeds from the
exercise of this warrant. Except for this warrant and certain commitments to
issue additional shares of our common stock upon the achievement of certain
milestones pursuant to the employment agreements of Chaim J. Lieberman, Dr.
Kanovsky and Simcha Edell, there are no outstanding options, other warrants, or
rights to purchase any of our securities.
If the warrants are exercised, we will receive $500,000. If the total net
proceeds are raised by us pursuant to this registration statement ($4.5M), the
proceeds from this warrant will be reserved by us for future operating expenses.
If less than the total amount of the offering is raised by us, and depending on
the timing of the exercise of the warrants by the warrant holder, this amount
may be utilized as additional capital in order to conduct the Phase I/II
clinical trials, or to fund further research & development and working capital.
DIVIDENDS
We do not expect to pay dividends. Dividends, if any, will be contingent
upon our revenues and earnings, if any, capital requirements and financial
conditions. The payment of dividends, if any, will be within the discretion of
our Board of Directors. We presently intend to retain all earnings, if any, for
use in its business operations and accordingly, the Board of Directors does not
anticipate declaring any dividends in the foreseeable future.
EXPERTS
The validity of the common stock offered in this Offering was passed upon for us
by _____________________. Our financial statements for the year ended December
31, 2005 for the period May 18, 2004 (inception) to December 31, 2004 and for
the period May 18, 2004 (Inception) to December 31, 2005, appearing in this
prospectus and this registration statement have been audited by Meyler &
Company, LLC, independent auditors, as set forth in their report thereon, which
contains an explanatory paragraph with respect to the uncertainty surrounding
our ability to continue as a going concern, appearing elsewhere herein, and are
included in reliance upon such report given upon the authority of such firm as
experts in accounting and auditing.
INTEREST OF NAMED EXPERTS AND COUNSEL
No expert or counsel named in this prospectus as having prepared or certified
any part of this prospectus or having given an opinion upon the validity of the
securities being registered or upon other legal matters in connection with the
registration or offering of the common shares was employed on a contingency
basis or had, or is to receive, in connection with the offering, a substantial
interest, directly or indirectly, in the registrant or any of its parents or
subsidiaries. Nor was any such person connected with the registrant or any of
its parents, subsidiaries as a promoter, managing or principal underwriter,
voting trustee, director, officer or employee.
DISCLOSURE OF SEC POSITION OF
INDEMNIFICATION FOR SECURITIES ACT LIABILITIES
Our bylaws provide that directors and officers (and any person who acted at our
request as an officer or director) shall be indemnified by us to the fullest
extent authorized by the general corporate laws of Nevada, against all expenses
and liabilities reasonably incurred in connection with services for us or on our
behalf if:
27
o Such person acted in good faith with a view to our best interests;
and
o In the case of a monetary penalty in connection with a criminal or
administrative action or proceeding, such person had reasonable
grounds to believe that his or her conduct was lawful.
Insofar as indemnification for liabilities arising under the Securities Act
might be permitted to directors, officers or persons controlling our company
under the provisions described above, we have been informed that in the opinion
of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Securities Act and is therefore unenforceable.
ORGANIZATION WITHIN THE LAST FIVE YEARS
From January 2005 to May 2005, Mazal rented office space in the home of Mr James
B. Wiegand for a total amount of $12,000.
On June 6, 2005, we became contractually obligated to exchange 20,000,000 shares
of our common stock for 7,000,000 shares of Delaware Mazal with Advanced Plant
Pharmaceuticals, Inc. pursuant to the Share Exchange Agreement, dated June 6,
2005. On July 6, 2005 we issued to Advanced Plant Pharmaceuticals, Inc.
10,500,000 of our common stock and on January 16, 2006 we issued to Advanced
Plant Pharmaceuticals, Inc. the remaining amount of 9,500,000 shares of our
common stock due pursuant to the Share Exchange Agreement, dated June 6, 2005.
On June 30, 2005, we issued to Malcolm Jennings 3,800,000 shares of our common
stock in a private placement at $0.0658 per share realizing $250,000.
In January 2005 Advanced Plant Pharmaceuticals, Inc., our majority shareholder,
subleased to us office space of approximately 2,500 square feet located at 43
West 33rd Street, New York, NY 10001 at a monthly rate of $750 pursuant for a
one-year sublease. In January 2006, in connection with the monthly office lease
assumed from APPI, we began charging $750 a month rent to Amazon Biotech, Inc.
("Amazon"). As of June 30, 2006, the amount due from Amazon was $4,500.
Currently our monthly lease payment to LBJ Realtors is $2,156 which does not
include electricity and other managerial services.
On January 25, 2006, we issued 100,000 shares of our common stock to Dr. Mechael
Kanovsky as performance bonuses. Dr. Kanovsky is also entitled to receive an
additional 100,000 shares of our common stock each time that the Delaware Mazal
receives an IND or a patent for one of our products under development.
On August 1, 2005, we authorized the issuance of and issued thereafter 500,000
shares of our common stock to Chaim J. Lieberman in consideration for his
services rendered to our subsidiary, Delaware Mazal, pursuant to an employment
Agreement, dated December 10, 2004, as amended on August 1, 2005, among Mr.
Lieberman, us, and Delaware Mazal.
28
On December 7, 2005 we authorized and on January 5, 2006 we issued to James B.
Wiegand 500,000 shares of our common stock in consideration for the services he
rendered to us regarding the merger during his appointment as our Chief
Executive Officer from 2003 to June 6, 2005.
On December 7, 2005, we authorized and on January 5, 2006 we issued to Max Gould
500,000 shares of our common stock in consideration for his participation in the
merger.
On December 15, 2005 we issued to Mr. Malcolm Jennings 149,500 shares of our
common stock as a penalty for a late registration filing pursuant to the terms
of a subscription agreement, dated May 19, 2005.
On December 19, 2005, Mr. Edell received 75,000 shares of our common stock in
consideration for his services rendered to our subsidiary, the Delaware Mazal,
pursuant to an Employment Agreement, dated November 9, 2005. Mr. Edell is
entitled to an additional 75,000 shares of our common stock at the end of his
first year of employment, as compensation for services rendered to Delaware
Mazal. In addition, Mr. Edell is entitled to the issuance of additional 75,000
shares of our common stock upon our receipt of one million dollars in funding.
On December 19, 2005, we issued to Malcolm Jennings 500,000 shares of our common
stock for services rendered as a penalty for a late registration filing pursuant
to the terms of a subscription agreement, dated May 19, 2005.
At December 31, 2004, the Delaware Mazal was indebted to Advanced Plant
Pharmaceuticals, Inc. ("APPI") for $50,732 for the transfer of technology
rights. In 2005, we made payments to APPI totaling $60,000 and paid expenses in
the amount of $5,749 on behalf of APPI. We were also charged rent by APPI in the
amount of $9,000. The balance due from APPI amounted to $6,267 at December 31,
2005. During the three months ended March 31, 2006, we paid expenses of $2,217
on behalf of APPI resulting in a balance due from APPI of $8,484 at March 31,
2006.
In April 2006, we issued to Mr. Malcolm Jennings 400,000 shares of our common
stock in consideration for $100,000.
Other than as set forth above, none of the following parties has, during the
last two years, had any material interest, direct or indirect, in any
transaction with us or in any proposed transaction that has or will materially
affect us:
o any of our directors or officers;
o any person proposed as a nominee for election as a director;
o any person who beneficially owns, directly or indirectly, shares
carrying more than 5% of the voting rights attached to our
outstanding shares of common stock; or
o any relative or spouse of any of the foregoing persons who has the
same house as such person.
29
DESCRIPTION OF BUSINESS
Our History
We were originally organized under the laws of the State of Colorado on April 9,
1998. Our only activity prior to June 6, 2005 had been attempts to locate and
negotiate with a business entity for the merger of that target company into the
predecessor of Mazal. Our operations consisted solely of seeking merger or
acquisition candidates, and we had no business operations or revenues.
On June 6, 2005, we underwent a change in control and adopted the current focus
of our business, which is the development, manufacture and supply of plant based
pharmaceuticals. In December 2004 Delaware Mazal acquired from Advanced Plant
Pharmaceutical Inc (APPI) a patent and the rights to manufacture and sell three
compounds or compositions that were in the possession of APPI. However, APPI
retained the right to sell APPI's cholesterol compositions (Lo-Chol) as an
over-the-counter nutraceutical. We modified APPI's HDL elevating composition and
on April 8, 2005 we submitted an initial new drug application to the FDA and on
June 2, 2005 we received approval from the FDA to conduct a phase I/II study on
this modified HDL raising composition. We have not started to work on the other
two compositions for the treatment of leukemia or Alzheimers.
Mazal is dedicated to using whole plants in order to develop healthier natural
pharmaceuticals for the treatment of human diseases. We are currently
concentrating its human and financial resources on the development and testing
of its HDL elevating drug MAHDL-01. When additional human and financial
resources become available to Mazal, we will decide on our priorities in
development of the other compositions.
As discussed above, on June 6, 2005, we acquired a majority interest in Delaware
Mazal pursuant to the Share Exchange Agreement. On June 6, 2005, a majority of
our common stock was acquired by Advanced Plant Pharmaceuticals, Inc., a
Delaware corporation, pursuant to the Share Exchange Agreement among Advanced
Plant Pharmaceuticals, Inc., Akid Corporation, and James B. Wiegand, who was one
of our principals at the time. Pursuant to the Share Exchange Agreement, we
agreed to issue to Advanced Plant Pharmaceuticals, Inc. 20,000,000 shares of our
common stock which represented 94.21 % of our issued and outstanding common
stock. In exchange, Advanced Plant Pharmaceuticals, Inc. transferred to us
7,000,000 shares of the common stock of Mazal Plant Pharmaceuticals, Inc., a
Delaware corporation (the "Delaware Mazal"), which represented 69% of the issued
and outstanding shares of the Delaware Mazal. For accounting purposes, such
transaction is characterized as a reverse merger between the Delaware Mazal and
us. Since such change in control, we, through Delaware Mazal, engage in the
development, manufacture, and distribution of plant-based pharmaceutical drugs
for the treatment of various human illnesses.
On November 9, 2005, we changed our state of incorporation from Colorado to
Nevada by our merger with our wholly owned subsidiary, Mazal Plant
Pharmaceuticals, Inc., a Nevada corporation. As a result of such merger, our
name was changed to Mazal Plant Pharmaceuticals, Inc. in order to better reflect
our business operations.
Principal Products and their Markets
Our lead drug candidate, MAHDL-01, is a drug designed to improve cholesterol
levels in individuals with unbalanced cholesterol levels.
We are also considering developing plant-based drugs for the treatment of
diabetes and Alzheimer's disease. Independent research published in the
scientific literature has documented a link between low HDL levels and an
increased incidence of diabetes including that an increase in HDL levels lowers
the risk of diabetes. Based on such literature, we are considering conducting
clinical studies with MAHDL-01 and with other versions of MAHDL-01 that are
specifically designed to help combat diabetes. Our staff in Israel is still in
the very early stages of combing the literature and choosing the plants that we
would ultimately combine for such a drug. However, research into our drugs for
diabetes is in its preliminary phases; further research depends on our
capability in manpower and funding.
Mazal commenced initial contacts with nutraceutical companies and such companies
have expressed an interest in purchasing "pharmaceutical grade" plants from
individuals and entities which can provide them with such a product.
Pharmaceutical grade plants are plants that are grown in controlled environments
in such a way as to minimize the batch to batch variabilities in active
ingredients among different batches of plants. Mazal has completed some
preliminary feasibility talks with different experts in the field and concluded
that when capital resources are available for this project we will consider
developing the capabilities necessary to become a world supplier of
pharmaceutical-grade medicinal plants for the neutraceutical, homeopathic, and
plant pharmaceutical markets.
30
MAHDL-01 is a drug consisting of various combinations of herbs. In order to
understand how MAHDL-01 works, it is important to understand that cholesterol
levels can be improved by either directly lowering bloodstream levels of
low-density lipoprotein, also known as "LDL" or "bad" cholesterol, or by raising
bloodstream levels of high-density lipoprotein, also known as "HDL" or "good"
cholesterol. HDL extracts cholesterol particles from the cholesterol deposits
attached to arterial walls and transports them to the liver, where they are
disposed of by the body. HDL also interferes with the accumulation of LDL
cholesterol deposits on the arterial walls. The risk of atherosclerosis and
heart attacks in both men and women is strongly related to HDL levels. High HDL
levels are associated with a lower risk. The lowering of levels of triglycerides
in the bloodstream also has a positive effect on cholesterol levels. It is our
hope that our MAHDL-01 drug balances cholesterol levels by improving the human
body's metabolic processes that naturally improve cholesterol levels by both
increasing HDL cholesterol levels and lowering triglyceride levels in the body.
There is a large potential market for a safe and effective treatment for
elevated cholesterol levels. Cardiovascular diseases are among the leading
causes of death worldwide, and high blood cholesterol (Hypercholesterolemia) is
one of the major risk factors for heart disease. Elevated LDL cholesterol in the
bloodstream collects on the walls of the arteries and causes the flow of blood
to the heart to be blocked.
Distribution Methods of the Products
We are currently searching for opportunities to enter into a joint venture with
a major pharmaceutical distribution company that already has the resources and
capabilities required to distribute our products throughout the United States
and internationally. Specifically, we are looking for a joint venturer who will
provide the following services:
o Complete the development of MAHDL-01;
o Submit the required documentation to the Food and Drug
Administration and secure approval for MAHDL-01;
o Support MAHDL-01 with pre-launch, launch and ongoing marketing and
support activities commensurate with the sales potential; and
o Dedicate and manage a sales force of sufficient numbers to maximize
the international market potential for MAHDL-01
Such joint venturer can be either a branded pharmaceutical company (perhaps one
with a drug whose patent rights are running out shortly) or, alternatively, one
of the major pharmaceutical generic manufacturers looking for its own brand.
31
Initial Studies, IND, Phase I and Phase II clinical trials
An initial study was performed in Australia on Lo-Chol, a precursor to our
MAHDL-01 drug formulation prior to the transfer of the compositions to Delaware
Mazal by APPI. In that study 400 patients were divided into four arms: (a)
low-fat diet arm; (b) Lo-Chol arm; (c) Lo-Chol + low fat diet arm; and (d)
placebo. The results after 6 months were that those subjects who took Lo-Chol
alone had an increase of almost 50% in their HDL ("good" cholesterol) levels and
a decrease of over 35% in their triglyceride levels. Those taking Lo-Chol with a
low-fat diet had a somewhat better outcome. Those on a low-fat diet alone had
about a 10% decrease in their triglyceride levels and about a 15-20% increase in
their HDL levels.
We have performed an initial toxicity study on laboratory rats. The laboratory
rats were fed a high dose of the drug and no toxicity was seen, i.e. no rats
died and all necroscopic studies came back normal.
Such initial studies have shown a promising trend on cholesterol levels without
major side effects therefore we applied for an IND from the FDA to do a Phase
I/II clinical trial to prove efficacy.
An IND filed with the FDA with respect to MAHDL-01 is presently effective. The
IND for MAHDL-01 was submitted on April 8, 2005, and approved on June 2, 2005.
MAHDL-01 has been approved by the FDA for Phase I/II clinical trials. The FDA
made some comments and requests for additional information. These comments and
requests do not have major implications for conducting the clinical trials.
The cost of conducting the Phase I/II trials is estimated to be between 1.0 and
1.6 million dollars. We are in negotiations with a number of CRO's and medical
facilities and we cannot provide assurances as to the final cost of the Phase I/
II trials which will be known when we execute an agreement with a CRO. The
currently planned study as approved in the IND is a Phase I/II study in 400
subjects. We are conducting quality control analysis of manufacturing suppliers
and facilities. The Preclinical studies have not been conducted yet but may be
later required by the FDA in line with the FDA's Guidance for Industry:
Botanical Drug Products (June 2004).
We estimate that the Phase I/II clinical trials will take one year from
enrolment to analysis of all statistical data. The ingredients that make up
MAHDL-01 are all from the GRAS (generally regarded as safe) list of the FDA. We
are inquiring as to the cost of clinical trial insurance for a drug that is made
up wholly of GRAS ingredients.
Mazal intends to conduct a combined Phase I/II study. This study will both test
the safety of the drug (Phase I) and the efficacy of the drug (Phase II). The
study is a Double blind, placebo and active controlled randomized, parallel
group study to evaluate the safety and efficacy of MAHDL-01 alone and as an
adjunct to statin therapy vs. placebo or statin therapy alone, in increasing HDL
in subjects with hypoalphalipoproteinanemia who are maintaining a restrictive
diet.
The study is a 4 arm, double blind, study. The four arms are as follows:
1. MAHDL + placebo
2. a statin + placebo
3. MAHDL + statin
4. placebo + placebo
Subjects will be enrolled in one of the above four arms and they will be taking
twice daily the pills that they are given for a period of 18 weeks. During that
time serum cholesterol levels and other indicators will be measured.
On November 17, 2005, we executed a Letter of Intent to enter into a possible
joint venture with Punzi Medical Center ("PMC") in connection with the
performance of the Phase I/II. In the event that Mazal completes Phase I/II in a
successful manner, then the parties shall proceed to Phase III human clinical
trials. The purpose of the joint venture is to obtain the FDA's approval to
conduct human clinical trials of MAHDL-01 and to conduct those human clinical
trials. Subject to the terms and conditions of the agreement, PMC will (a) fund
all costs and expenses incurred in connection with the clinical trials, (b) make
its facilities available for the conduct of the clinical trials, and (c) provide
consulting services to the us with respect to the conduct of the clinical trials
and their approval by the FDA. In consideration for the obligations of PMC, we
will pay royalties equal to an agreed upon percentage of the net revenues
generated by any sales of MAHDL-01 to PMC during an agreed upon time period
following the FDA's final approval.
On July 31, 2006, we entered into an Interim Letter of Agreement with Dr.
Veronica Motiram for a Phase I/II, double-blind, placebo and active controlled,
randomized, parallel-group study to evaluate the safety and efficacy of MAHDL-01
alone and as an adjunct to statin therapy, versus placebo or statin therapy
alone, in increasing HDL in subjects with hypoalphalipoproteinemia. The studies
shall be conducted at the Neuro Psychiatric Center of the Palm Beaches, Boynton
Beach, FLA. The agreement calls for a minimum number of subjects of ten and a
maximum of four hundred. Dr. Veronica Motiram will receive $2,500 per subject
who completes the study, where fifty percent (50%) will be paid in cash and the
remaining fifty percent (50%) will be paid in shares of the Company's common
stock.
Competition
Our product is designed to be a whole plant pharmaceutical attractive to the
natural supplement marketplace. We are engaged in a rapidly changing field
characterized by rapid technological change, new and improved product
introductions, changes in regulatory requirements and evolving industry
standards. Other products and therapies that will compete directly with the
products that we are seeking to develop currently exist or are being developed.
We expect competition from fully integrated pharmaceutical companies and more
established companies to be intense and to increase. These companies have
significantly greater financial resources and expertise in discovery and
development, manufacturing, preclinical and clinical testing, obtaining
regulatory approvals and marketing than we do. Many of our competitors have
significant products that have been approved or are in development and operate
large, well-funded discovery and development programs. Academic institutions,
governmental agencies and other public and private research organizations also
conduct research, seek patent protection and establish collaborative
arrangements for therapeutic products and clinical development and marketing. We
have none of these resources. In addition, we will face competition based on
product efficacy and safety, the timing and scope of regulatory approvals,
availability of supply, marketing and sales capability, reimbursement coverage,
pricing and barriers from patent positions of larger companies. We do not have
any experience in these areas at this time and therefore we are at a competitive
disadvantage.
32
Currently, the most widely used drugs that reduce elevated LDL is a group of
drugs known as Statins. Statins include atorvastatin (Lipitor), rosuvastatin
(Crestor), simvastatin (Zocor), and pravastatin (Pravachol). However, we believe
that we may have a competitive advantage over Statins because Statins have
significant side effects, including abdominal pain, muscle inflammation and
liver abnormalities. In addition, although these drugs lower LDL levels
significantly, they do not appreciably affect HDL or triglyceride levels.
Many of the Statins are nearing the end of their patent protection and drug
companies are scrambling to combine their statin drug with another drug in order
to extend their patent protection. MAHDL can be a strong candidate, as it
complements Statins by raising HDL levels while the Statins lower the LDL
levels.
Niacin is the most widely used drug that is used for the purpose of raising HDL
levels. However, up to 88% of patients experience flushing or hot flashes as a
side effect of Niacin, and there are other side effects as well. Fibrates such
as Lopid are successful in lowering triglycerides.
In addition, there are legions of natural dietary supplements sold as
nutraceuticals that claim to lower cholesterol. These over-the-counter
supplements range from fish oil (omega-3 fatty acids) to garlic, and from
circumin (turmeric) and guggul (gum resin) to Chlorella (microalgae), cinnamon,
calcium citrate, and pantethine (vitamin B-6), amongst others. The clinical
effects of these dietary supplements are controversial, and for the most part
are undocumented and unproven.
MAHDL-01 can be marketed as a whole plant medicine, and attract that part of the
marketplace interested in natural plant substances.
Once MAHDL-01 has successfully passed Phase II clinical trials, we intend to
form a strategic partnership for co-development and co-marketing with a major
player in the market in order to maximize the sales opportunity for MAHDL-01.
Specifically, we are looking for a partner who will help perform the following
activities:
o Complete the development program;
o Submit the required documentation to FDA and secure approval for the
product;
o Support the product with pre-launch, launch and ongoing marketing
and support activities commensurate with the sales potential; and
o Dedicate and manage a sales force of sufficient numbers to maximize
the international market potential for MAHDL
33
Sources and Availability of Raw Materials; Names of Principal Suppliers
Active pharmaceutical ingredients and other materials and supplies that we use
in our operations are generally available and purchased from many different
foreign and domestic suppliers, including Mother Herbs, Schen Yang ParmUn and
IndoWorld. For the period of the clinical trials, we plan to outsource farming
to existing producers according to our specifications. There is no guarantee
that we will have timely and sufficient access to a critical raw material or
finished product. A prolonged interruption in the supply of a single-sourced
active ingredient or finished product could cause our financial position and
results of operations to be materially adversely affected.
MAHDL-01 is to be manufactured using qualified raw material suppliers,
outsourced powder facilities and a formulation plant, all working in compliance
with good manufacturing practices. We have not finalized these operations as we
are in negotiations with a quality control consultant to qualify these
facilities.
As research and development funding becomes available to us, we will consider
working in consultation with experts to develop the capability to farm some of
the plants we use as raw materials especially those with the more significant
problems of standardization..
Intellectual Property
We own the pharmaceuticals rights to a U.S. patent known as Drug Formulation 1
patent number 5,707,631 filed on April 30, 1996. Such patent will expire in
2013. In July 2006, we filed a U.S. provisional patent application for an
improved version of the Drug formulation 1, known as MAHDL-01, and such
application is still pending. There can be no assurance that the pending patent
application will result in issued patents, that patents, trademarks or trade
names issued to us will not be challenged or circumvented by competitors, or
that such patents, trademarks or trade names will be found to be valid or
sufficiently broad to protect our proprietary technology or to provide us with a
competitive advantage.
Governmental Regulation
Our product is subject to extensive governmental regulation, including the
Federal Food, Drug, and Cosmetic Act, as amended, the Public Health Service Act,
also as amended, as well as other federal, state, and local statutes and
regulations. These laws, and similar laws outside the U.S., govern the clinical
and non-clinical testing, manufacture, safety, effectiveness, approval,
labeling, distribution, sale, import, export, storage, record keeping,
reporting, advertising and promotion of our products, if approved. Violations of
regulatory requirements at any stage may result in various adverse consequences,
including regulatory delay in approving or refusal to approve a product,
enforcement actions, including withdrawal of approval, labeling restrictions,
seizure of products, fines, injunctions and/or civil or criminal penalties. Any
product that we develop must receive all relevant regulatory approvals or
clearances before it may be marketed.
The regulatory process, which includes extensive pre-clinical testing and
clinical trials of each clinical candidate to study its safety and efficacy, is
uncertain, takes many years and requires the expenditure of substantial
resources. We cannot assure you that the clinical trials of our product
candidates under development will demonstrate the safety and efficacy of those
product candidates to the extent necessary to obtain regulatory approval.
34
FOOD AND DRUG ADMINISTRATION
Our product is subject to regulation by the Food and Drug Administration (the
"FDA") and other authorities. The activities required by the FDA before a
product such as MAHDL-01 may be marketed in the United States are generally
performed in the following sequential steps:
1. Pre-clinical testing. This includes laboratory testing of our products
in animals to determine safety, efficacy and potential toxicity. Pre-clinical
studies must be conducted by laboratories that comply with FDA regulations
regarding good laboratory practice.
2. Submission to the FDA of an IND. The results of pre-clinical studies,
together with manufacturing information, analytical data and proposed clinical
trial protocols, are submitted to the FDA as part of an IND, which must become
effective before the clinical trials can begin. Once the IND is filed, the FDA
has 30 days to review it. The IND will automatically become effective 30 days
after the FDA receives it, unless the FDA indicates prior to the end of the
30-day period that the proposed protocol raises concerns that must be resolved
to the FDA's satisfaction before the trials may proceed. If the FDA raises
concerns, we may be unable to resolve the proposed protocol to the FDA's
approval in a timely fashion, if at all.
3. Completion of clinical trials. Human clinical trials are necessary to
obtain approval for a new drug or biological product and typically involve a
three-phase process. In Phase I, small clinical trials are generally conducted
to determine the safety of the product. In Phase II, clinical trials are
generally conducted to assess safety, acceptable dose, and gain preliminary
evidence of the efficacy of the product. In Phase III, clinical trials are
generally conducted to provide sufficient data for the statistically valid proof
of safety and efficacy. Clinical trials must be conducted according to good
clinical practices under protocols that detail the trial's objectives, inclusion
and exclusion criteria, the parameters to be used to monitor safety and the
efficacy criteria to be evaluated, and informed consent must be obtained from
all study subjects. Each protocol must be submitted to the FDA as part of the
IND. The FDA may impose a clinical hold on an ongoing clinical trial if, for
example, safety concerns arise, in which case the study cannot recommence
without FDA authorization under terms sanctioned by the agency. In addition,
before a clinical trial can be initiated, each clinical site or hospital
administering the product must have the protocol reviewed and approved by an
independent institutional review board ("IRB"). The independent IRB will
consider, among other things, ethical factors and the safety of human subjects.
The independent IRB may require changes in a protocol, which may delay
initiation or completion of a study. Phase I, Phase II or Phase III clinical
trials may not be completed successfully within any specific period of time, if
at all, with respect to any of our potential products. Furthermore, we, the FDA
or an independent IRB may suspend a clinical trial at any time for various
reasons, including a finding that the healthy individuals or the patients are
being exposed to an unacceptable health risk.
4. Submission to the FDA of a New Drug Application ("NDA"). After
completion of clinical studies for a biological product, a New Drug Application
("NDA") is submitted to the FDA for product marketing approval. No action can be
taken to market any new drug or biologic product in the United States until the
FDA has approved an appropriate marketing application.
35
5. FDA review and approval of the NDA before the product is commercially
sold or shipped. The results of pre-clinical studies and clinical trials and
manufacturing information are submitted to the FDA in the form of an NDA for
approval of the manufacture, marketing and commercial shipment of the product.
The FDA may take a number of actions after the NDA is filed, including but not
limited to, denying the NDA if applicable regulatory criteria are not satisfied,
requiring additional clinical testing or information; or requiring post-market
testing and surveillance to monitor the safety or efficacy of the product.
Adverse events that are reported after marketing approval can result in
additional limitations being placed on the product's use and, potentially,
withdrawal of the product from the market. Any adverse event, either before or
after marketing approval, can result in product liability claims against us.
MEDICAID AND MEDICARE
Medicaid, Medicare and other reimbursement legislation or programs govern
reimbursement levels and require all pharmaceutical manufacturers to rebate a
percentage of their revenues arising from Medicaid-reimbursed drug sales to
individual states.
ENVIRONMENT
We believe that our operations comply in all material respects with applicable
laws and regulations concerning the environment. While it is impossible to
predict accurately the future costs associated with environmental compliance and
potential remediation activities, compliance with environmental laws is not
expected to require significant capital expenditures and has not had, and is not
expected to have, a material adverse effect on our earnings or competitive
position.
PRODUCT LIABILITY
The sale of pharmaceutical products can expose the manufacturer of such products
to product liability claims by consumers. A product liability claim, if
successful and in excess of our insurance coverage, if any, could have a
material adverse effect on our financial condition.
OUR FACILITIES
We conduct our administration and intend to conduct clinical trials in our US
offices and we conduct our research and product development in our Jerusalem
office, all as described below in "Description of Properties".
EMPLOYEES
We have four part-time employees in administration and two part-time employees
in operations
36
DESCRIPTION OF PROPERTY
From January 2005 through December 2005, we leased office space of approximately
2,500 square feet located at 43 West 33rd Street, New York, NY 10001 at a
monthly rate of $750 pursuant to a month to month sublease from Advanced Plant
Pharmaceuticals, Inc., our majority shareholder. In January 2006, we assumed
payments, from Advanced Plant Pharmaceuticals, Inc., on its corporate office
space in New York. The monthly lease payment is in the aggregate amount of
$2,181. In addition, we pay 35% of the space's electricity cost. In January
2006, we began subleasing to Amazon Biotech, Inc. for a payment of $750 per
month. As of June 30, 2006 Amazon Biotech owes us $4,500. We also lease office
space of approximately 1,000 feet at Beit Offer Building, 5 Nahum Hefzadi
Street, Jerusalem, Israel on a month to month basis having a monthly rate of
$2,265 (not including municipal taxes). Prior to June 6, 2005, we used office
space in the home of James B. Wiegand, Akid Corporation's then President.
We may need to expand our offices in Jerusalem if we choose to establish our own
research and development laboratory. This will allow us to process small batches
of new compounds/combinations internally, for initial in vitro and/or animal
studies. Such a laboratory would likely include basic quality control testing,
to ensure that we are not losing activity of active ingredients after the
processing. This laboratory would require a dedicated room, of about 100 square
feet, and equipment. The set-up cost would be roughly $100,000 to $150,000 and
such a laboratory would take approximately three months to set up.
Net rent expense for the three months ended March 31, 2006 and 2005, the year
ended December 31, 2005 and for the period May 18, 2004 (Inception) to March 31,
2006 amounted to $16,459, $2,250, $30,500 and $46,959, respectively. There was
no rent expense for the period May 18, 2004 (inception) to December 31, 2004.
Mazal's current office space - both its main New York office and its satellite
Jerusalem office - are suitable for its present needs, and the foreseeable
future. There is work space for all staff members, meeting rooms, and adequate
storage; and the New York office has space available for growth.
MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
Plan of Operation.
We intend to engage in the development and sale of plant-based pharmaceutical
drugs through the Delaware Mazal. We intend to commence with Phase I/II studies
when we raise the full amount of funds needed to do the study. The trial itself
should take about a year to complete with enrolment taking about 3 months, the
trial itself taking 6 months, and analysis of the data and generation of a
report an additional 3 months. The funding sources for the trial will be from
investors who subscribe to the shares being offered in this registration
statement. After we sign an agreement with a Clinical Research Organization
(CRO) or a medical facility to conduct the trial, the amount of funding needed
for the trial will be put in a separate escrow account and will be used
specifically to pay for the trial. The cost of conducting the Phase I/II trials
is estimated to be between 1.0 and 2.0 million dollars.
GOAL DATE Est. cost
- ---------------------------------------------------- ---------- ----------
Hire Clinical Reasearch Organization (CRO) Q1 2007 $1,000,000
Procure ingredients and produce MAHDL-01 and placebo Q1 2007 $ 25,000
Complete contract negotiations with medical centers Q1 2007
Contract with pharmaceutical company for use of
statin and placebo for phase I/II study Q1 2007
Finalize all other aspects of the phase I/II study
such as drug labeling, randomization protocol, and
other services needed for study. Q1 2007
Begin multinational phase I/II studies for MAHDL in
major medical Centers Q2 2007 $1,000,000
Supervision of ongoing phase I/II drug trial Q1-Q3 2007
Set up small in-house QC laboratory Q3 2007 $ 100,000
Resume MADIA diabetes drug research program -
animal trials Q4 2007 $ 20,000
MADIA - patent and FDA applications Q4 2007 $ 30,000
Enter negotiations with potential JV partner for
MAHDL-01 Phase III clinical studies Q1 2008
On November 17, 2005, we executed a Letter of Intent to enter into a possible
joint venture with Punzi Medical Center ("PMC") in connection with the
performance of the Phase II and Phase III human clinical trials of MAHDL-01.
Subject to the terms and conditions of the agreement, PMC will (a) fund all
costs and expenses incurred in connection with the clinical trials, (b) make its
facilities available for the conduct of the clinical trials, and (c) provide
consulting services to us with respect to the conduct of the clinical trials and
their approval by the FDA. In consideration for the obligations of PMC, we will
pay royalties equal to an agreed upon percentage of the net revenues generated
by any sales of MAHDL-01 to PMC during an agreed upon time period following the
FDA's final approval.
On July 31, 2006, we entered into an Interim Letter of Agreement with Dr.
Veronica Motiram for a Phase I/II, double-blind, placebo and active controlled,
randomized, parallel-group study to evaluate the safety and efficacy of MAHDL-01
alone and as an adjunct to statin therapy, versus placebo or statin therapy
alone, in increasing HDL in subjects with hypoalphalipoproteinemia. The studies
shall be conducted at the Neuro Psychiatric Center of the Palm Beaches, Boynton
Beach, FLA. The agreement calls for a minimum number of subjects of ten and a
maximum of four hundred. Dr. Veronica Motiram will receive $2,500 per subject
who completes the study, where fifty percent (50%) will be paid in cash and the
remaining fifty percent (50%) will be paid in shares of the Company's common
stock.
To meet our needs for cash, we are attempting to raise money from this offering.
We intend to sell up to a maximum of 10,000,000 shares of our common stock
through this offering, which would generate up to $4,500,000 in proceeds. We
believe that this will allow us to begin our clinical studies and remain in
business for twelve months. If we raise less than the maximum amount and need
additional funds, we may seek to obtain additional funds.
37
GOING CONCERN CONSIDERATION
As shown in the accompanying financial statements, we have incurred net losses
of $4,985,389 since inception and has a negative working capital of $293,263 at
June 30, 2006. Management's plans include the raising of capital through the
equity markets to fund future operations, seeking additional acquisitions, and
the generating of revenue through its business. Failure to raise adequate
capital and generate adequate sales revenues could result in our having to
curtail or cease operations. Additionally, even if we do not raise sufficient
capital to support our operating expenses and generate adequate revenues, there
can be no assurances that the revenue will be sufficient to enable us to develop
business to a level where it will generate profits and cash flows from
operations. These matters raise substantial doubt about our ability to continue
as a going concern. However, the accompanying financial statements have been
prepared on a going concern basis, which contemplates the realization of assets
and satisfaction of liabilities in the normal course of business. These
financial statements do not include any adjustments relating to the recovery of
the recorded assets or the classification of the liabilities that might be
necessary should we be unable to continue as a going concern.
OFF-BALANCE SHEET ARRANGEMENTS
We have no off-balance sheet arrangements.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
At December 31, 2004, we were indebted to Advanced Plant Pharmaceuticals, Inc.
(APPI) for $50,732 for the acquisition of certain technology rights. In 2005, we
made payments to APPI totaling $60,000 and paid expenses in the amount of $5,749
on behalf of APPI. We were also charged rent by APPI in the amount of $9,000.
The balance due from APPI amounted to $6,267 at December 31, 2005. During the
three months ended March 31, 2006, we paid expenses of $2,217 on behalf of APPI
resulting in a balance due from APPI of $8,484 at June 30, 2006.
From January 2005 to May 2005, we rented office space in the home of Mr. James
B. Wiegand for a total amount of $12,000.
In January 2005 Advanced Plant Pharmaceuticals, Inc., our majority shareholder,
subleased to us office space of approximately 2,500 square feet located at 43
West 33rd Street, New York, NY 10001 at a monthly rate of $750 pursuant to a
one-year sublease. In January 2006, in connection with the monthly office lease
assumed from APPI, we began charging $750 a month rent to Amazon Biotech, Inc.
("Amazon"), a company that has several employees and stockholders in common. At
June 30, 2006, the amount due from Amazon was $4,500. The monthly lease payment
is $2,156 which does not include electricity and other managerial services.
On January 25, 2006, we issued 100,000 shares of our common stock to Dr. Mechael
Kanovsky as a performance bonus. Dr. Kanovsky is also entitled to receive
100,000 shares of our common stock each time that we receive an IND or a patent
for one of our products under development.
38
On June 6, 2005, we became contractually obligated to exchange 20,000,000 shares
of our common stock for 7,000,000 shares of Delaware Mazal with Advanced Plant
Pharmaceuticals, Inc. pursuant to the Share Exchange Agreement, dated June 6,
2005. On July 6, 2005 we issued to Advanced Plant Pharmaceuticals, Inc.
10,500,000 of our common stock and on January 16, 2006 we issued to Advanced
Plant Pharmaceuticals, Inc. the remaining amount of 9,500,000 shares of our
common stock due pursuant to the Share Exchange Agreement, dated June 6, 2005.
On June 30, 2005, we issued to Malcolm Jennings 3,800,000 shares of our common
stock in a private placement at $0.0658 per share realizing $250,000.
On August 1, 2005, we authorized the issuance of and issued subsequently
thereafter 500,000 shares of our common stock to Chaim J. Lieberman in
consideration for his services rendered to our subsidiary, Delaware Mazal,
pursuant to an employment Agreement, dated December 10, 2004, as amended on
August 1, 2005, among Mr. Lieberman, us, and Delaware Mazal.
On December 7, 2005 we authorized and on January 5, 2006 we issued to James B.
Wiegand 500,000 shares of our common stock in consideration for the services he
rendered to us regarding the merger during his term as our Chief Executive
Officer from 2003 to June 6, 2005.
On December 7, 2005, we authorized and on January 5, 2006 we issued to Max Gould
500,000 shares of our common stock in consideration for his participation in the
merger.
On December 15, 2005 we issued to Mr. Malcolm Jennings 149,500 shares of our
common stock as a penalty for a late registration filing.
On December 19, 2005, we issued 500,000 shares of our common stock to Malcolm
Jennings as a penalty for a late registration filing.
On December 19, 2005, Mr. Edell received 75,000 shares of our common stock in
consideration for his services rendered to our subsidiary, the Delaware Mazal,
pursuant to an Employment Agreement, dated November 9, 2005. Mr. Edell is
entitled to an additional 75,000 shares of our common stock at the end of his
first year of employment, as compensation for services rendered to Delaware
Mazal. In addition, Mr. Edell is entitled to the issuance of additional 75,000
shares of our common stock upon our receipt of one million dollars in funding.
39
On April 25, 2006, we issued 400,000 shares of our common stock to Malcolm
Jennings in consideration for $100,000. The shares were issued under Regulation
S promulgated by the Securities and Exchange Commission.
Other than as set forth above, none of the following parties has, during the
last two years, had any material interest, direct or indirect, in any
transaction with us or in any presently proposed transaction that has or will
materially affect us:
o any of our directors or officers;
o any person proposed as a nominee for election as a director;
o any person who beneficially owns, directly or indirectly, shares
carrying more than 5% of the voting rights attached to our
outstanding shares of common stock; or
o any relative or spouse of any of the foregoing persons who has the
same house as such person.
MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
MARKET INFORMATION
Our stock is traded on the Pink Sheets under the symbol of MZPP.PK.
ENDED BID PRICES
----------------
CALENDAR QUARTER HIGH LOW
- ------------------ ------ ------
FISCAL YEAR 2005
March 31, 2005 $.0000 $.0000
June 30, 2005 $.0000 $.0000
September 30, 2005 $0.600 $.0500
December 31, 2005 $1.500 $.5000
FISCAL YEAR 2006
March 31, 2006 $1.150 $.2500
June 30, 2006 $.8500 $.2000
September 30, 2006 $0.950 $.2500
HOLDERS
On March 31, 2006, there were approximately 91 holders of record of our common
stock.
40
DIVIDENDS
We have not declared or paid any cash dividends on our common stock nor do we
anticipate paying any in the foreseeable future. Furthermore, we expect to
retain any future earnings to finance our operations and expansion. The payment
of cash dividends in the future will be at the discretion of our Board of
Directors and will depend upon our earnings levels, capital requirements, any
restrictive loan covenants and other factors the Board considers relevant.
WARRANTS OR OPTIONS
We have one outstanding warrant to purchase 1,000,000 shares of our common
stock, which we issued on October 31, 2005 to Luc Verelst. The warrant exercise
price is $0.50 per share and the exercise period is through October 30, 2008.
Except for the foregoing warrant to Luc Verelst, and stock based bonus
commitments in employment agreements of Chaim J. Lieberman, Dr. Kanovsky and
Simcha Edell, no warrants, options, or other securities convertible or
exchangeable into equity securities were issued or outstanding as of December
31, 2005 or as of date of this prospectus.
EQUITY COMPENSATION PLANS
In October 2005, we authorized the 2005 Stock Compensation Plan and 3,500,000
shares of our common stock were reserved for awards to employees, officers,
directors, consultants and other individuals providing services to Mazal and
Delaware Mazal.
PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
We made no purchases of our equity securities nor were any such purchases made
by any purchaser affiliated with us.
OUR TRANSFER AGENT
We have appointed Manhattan Stock Transfer, with offices at P.O. Box 756, Miller
Place, NY 11764, phone number, (631) 928-7655, facsimile: (631) 928-6171 as
transfer agent for our common shares. The transfer agent is responsible for all
record-keeping and administrative functions in connection with our common
shares.
EXECUTIVE COMPENSATION
The following table presents all information regarding the compensation awarded
to, earned by, or paid to Mazal's named executive offices for the fiscal year
ended December 31, 2005 and during the last three fiscal years.
41
SUMMARY COMPENSATION TABLE
Long Term All Other
Annual Compensation Compensation Awards Compensation ($)
------------------- ------------------- ----------------
Securities
Name and Restricted Stock Underlying
Principal Position Year Salary ($) Bonus ($) Awards ($) Options (#)
- ------------------ ---- ---------- --------- ---------- -----------
James B. 2005 0 0 $625,000 0 0
Wiegand 2004 0 0 0 0 0
Chief Executive Officer 2003 0 0 0 0 0
- ---------------------------------------------------------------------------------------------------------------
Mechael Kanovsky Chief
Executive Officer 2004 8,000 0 $30 0 0
2005 63,000 0 $10
- ---------------------------------------------------------------------------------------------------------------
Sam Berkowitz
Secretary 2004 0 0 $90 0 0
2005 36,000 0 0 0 0
- ---------------------------------------------------------------------------------------------------------------
Simcha Edell
CFO 2005 $17,400 0 $82,500 0 0
- ---------------------------------------------------------------------------------------------------------------
(1) Mr. Wiegand was our Chief Executive Officer and a director from 2003 through
June 6, 2005, when he resigned as a result of our change in control. Mr. Wiegand
received in the aggregate 500,000 shares of our common stock in consideration
for services he rendered to us.
(2) On June 6, 2005, Mechael Kanovsky replaced Mr. Wiegand as our Chief
Executive Officer.
We did not grant any options to any employee or executive officers during the
period May 18, 2004 (inception) to December 31, 2005.
There are employment agreements between Delaware Mazal and Dr. Mechael Kanovsky,
Sam Berkowitz and Simcha Edell.
Pursuant to the terms of the Employment Agreement, dated December 10, 2004, as
amended on August 1, 2005, among Mechael Kanovsky, us, and the Delaware Mazal,
Dr. Kanovsky was appointed President and Chief Executive Officer of the Delaware
Mazal for two years commencing November 1, 2004. The base salary is $48,000 per
year which was increased to $66,000 upon our receipt of the first IND. In
addition, Dr. Kanovsky received 800,000 shares of our common stock. Upon the
receipt of each additional IND, Dr. Kanovsky shall receive an additional 100,000
shares of our common stock. For each patent received by the Delaware Mazal, he
shall receive an additional 100,000 shares of our common stock and if Mazal
obtains a minimum of $2 million in funding or enters into a joint venture
arrangement, his annual base salary shall increase to $83,400.
Pursuant to the terms of the Employment Agreement, dated December 10, 2004, as
amended on August 1, 2005, among Mr. Berkowitz, us, and the Delaware Mazal, Mr.
Berkowitz was appointed as the Secretary of the Delaware Mazal for two years
commencing January 2, 2005. His base salary is $36,000 per year. As additional
compensation, Mr. Berkowitz was issued 1,800,000 shares of our common stock.
42
Pursuant to the terms of the Employment Agreement dated November 9, 2005,
between Mr. Edell and our subsidiary, the Delaware Mazal, Mr. Edell received
75,000 shares of our common stock. In addition, Mr. Edell is entitled to 75,000
shares of our common stock upon our receipt of one million dollars in funding,
and another 75,000 shares of our common stock at the end of twelve months of
employment with us, as compensation for his services rendered to Delaware Mazal.
The base salary is $34,800, to be increased to $42,000 upon our receipt of at
least one million dollars in funding.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE
On August 12, 2005, we dismissed Cordovano and Honeck LLP (the "Former
Accountant") from serving as our principal independent accountants. On August
12, 2005, we retained Meyler & Co. (the "New Accountant") as our new principal
independent accountants. The decision to change accountants was recommended and
approved by our Board of Directors.
THE FORMER ACCOUNTANT
The reports of the Former Accountant on the financial statements for either of
the past two fiscal years contained no adverse opinion or disclaimer of opinion,
and were not qualified or modified as to audit scope, or accounting principles.
The reports have been modified as to uncertainty as a going concern. In
addition, during our two most recent fiscal years and through August 12, 2005,
there were no disagreements with the Former Accountant on any matters of
accounting principles or practices, financial statement disclosure, or auditing
scope or procedures, which disagreements, if not resolved to the satisfaction of
the Former Accountant, would have caused it to make reference to the subject
matter of the disagreements in connection with its reports. None of the
reportable events set forth in Item 304(a)(1)(iv)(B) of Regulation S-B occurred
within our two most recent fiscal years nor through August 12, 2005.
We have provided the Former Accountant with a copy of this disclosure and has
requested that the Former Accountant furnish it with a letter addressed to the
U.S. Securities and Exchange Commission ("SEC") stating whether it agrees with
the above statements, and if not, stating the respects in which it does not
agree. A copy of the letter from the Former Accountant addressed to the SEC,
dated August 12, 2005 is filed as Exhibit 16.1 to our Current Report on Form
8-K, dated August 12, 2005, filed on August 12, 2005.
THE NEW ACCOUNTANT
During our two most recent fiscal years and through August 12, 2005: (1) we did
not consult the New Accountant regarding either the application of accounting
principles to a specified transaction, either completed or proposed, or the type
of audit opinion that might be rendered on Registrant's financial statements;
(2) neither a written report nor oral advice was provided to the Registrant by
the New Accountant that they concluded was an important factor considered by the
Registrant in reaching a decision as to the accounting, auditing or financial
reporting issue; and (3) we did not consult the New Accountant regarding any
matter that was either the subject of a "disagreement" (as defined in Item
304(a)(1)(iv) of Regulation S-B and the related instructions) or any of the
reportable events set forth in Item 304(a)(1)(iv)(B) of Regulation S-B.
43
MAZAL PLANT PHARMACEUTICAL, INC.
(Formerly AKID Corporation)
(A Development Stage Corporation)
FINANCIAL STATEMENTS
FOR THE YEARS ENDED
DECEMBER 31, 2005 AND 2004
AND THE SIX MONTHS ENDED
JUNE 30, 2006 (UNAUDITED)
CONTENTS
- --------------------------------------------------------------------------------
Page
Report of Independent Registered Public Accounting Firm F 1
Balance Sheets F 2
Statements of Operations F 3
Statements of Cash Flows F 4
Statement of Stockholders' Deficit F 5
Notes to Financial Statements F 6
44
MEYLER & COMPANY, LLC
CERTIFIED PUBLIC ACCOUNTANTS
ONE ARIN PARK
1715 HIGHWAY 35
MIDDLETOWN, NJ 07748
Report of Independent Registered Public Accounting Firm
To the Board of Directors
Mazal Plant Pharmaceutical, Inc.
We have audited the accompanying balance sheets of Mazal Plant Pharmaceutical,
Inc. (formerly AKID Corporation) (a development stage corporation) as of
December 31, 2005 and 2004 and the related statements of operations,
stockholders' deficit, and cash flows for the year ended December 31, 2005 and
the period May 18, 2004 (Inception) to December 31, 2004. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audits to obtain reasonable assurance about whether the
financial statements are free of material misstatement. The Company is not
required to have, nor were we engaged to perform, an audit of its internal
control over financial reporting. Our audits included consideration of internal
control over financial reporting as a basis for designing audit procedures that
are appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the Company's internal control over financial
reporting. Accordingly, we express no such opinion. An audit includes examining,
on a test basis, evidence supporting the amounts and disclosures in the
financial statements, assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of the Company as of December 31,
2005 and 2004 and the results of its operations and its cash flows for the year
ended December 31, 2005 and the period May 18, 2004 (inception) to December 31,
2004 in conformity with accounting principles generally accepted in the United
States of America.
The accompanying financial statements have been prepared assuming the Company
will continue as a going concern. As discussed in Note A to the financial
statements, the Company has negative working capital of $135,267, an accumulated
deficit of $4,365,110, and there are existing uncertain conditions which the
company faces relative to its obtaining capital in the equity markets. These
conditions raise substantial doubt about its ability to continue as a going
concern. Management's plans regarding those matters are also described in Note
A. The financial statements do not include any adjustments that might result
from the outcome of this uncertainty.
See also Note E regarding significant related party stock transactions for
services rendered to the Company and stock issued in 2005 and 2004.
/s/ Meyler & Company, LLC
Middletown, NJ
June 8, 2006
F-1
MAZAL PLANT PHARMACEUTICAL, INC.
(Formerly AKID Corporation)
(A Development Stage Corporation)
BALANCE SHEETS
ASSETS
June 30, December 31,
2006 2005 2004
----------- ----------- -----------
(Unaudited)
CURRENT ASSETS
Cash $ 3,282 $ 11,487
Prepaid salaries - officers 9,882 31,550
----------- ----------- -----------
Total Current Assets 13,164 43,037
OTHER ASSETS
Technology rights 50,700 50,700 $ 50,700
Due from affiliated companies 12,984 6,267
----------- ----------- -----------
Total Other Assets 63,684 56,967 50,700
----------- ----------- -----------
Total Assets $ 76,848 $ 100,004 $ 50,700
=========== =========== ===========
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable $ 46,554 $ 57,086
Accrued expenses 95,973 41,200 $ 633
Accrued salaries - stockholder 46,400 30,018 12,100
Loan payable - stockholder 50,000 50,000
Deposits to acquire stock 67,500
Due to Advanced Plant Pharmaceuticals, Inc. 50,732
----------- ----------- -----------
Total Current Liabilities 306,427 178,304 63,465
STOCKHOLDERS' DEFICIT
Preferred stock, no par value; authorized
1,000,000 shares; none issued and outstanding
Common stock authorized 100,000,000 shares;
no par value; issued and outstanding 38,180,500,
37,280,500 and 27,410,000 shares at June 30, 2006,
December 31, 2005 and 2004, respectively 4,755,810 4,286,810 2,673
Accumulated deficit (4,985,389) (4,365,110) (15,438)
----------- ----------- -----------
Total Stockholders' Deficit (229,579) (78,300) (12,765)
----------- ----------- -----------
Total Liabilities and Stockholders' Deficit $ 76,848 $ 100,004 $ 50,700
=========== =========== ===========
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS.
F-2
MAZAL PLANT PHARMACEUTICAL, INC.
(Formerly AKID Corporation)
(A Development Stage Corporation)
STATEMENTS OF OPERATIONS
For the Period For the Period
For the Six May 18, 2004 May 18, 2004
Months Ended For the (Inception) (Inception)
------------ Year Ended to to
June 30, June 30, December 31, December 31, June 30,
2006 2005 2005 2004 2006
------------ ------------ ------------- --------------- --------------
Restated and
(Unaudited) (Unaudited) (Unaudited)
COSTS AND EXPENSES
Compensation - stockholder $ 221,400 $ 107,215 $ 318,810 $ 13,466 $ 553,676
General and administrative expenses 398,879 111,172 4,030,862 312 4,430,053
------------ ------------ ------------ ------------ ------------
Total Costs and Expenses 620,279 218,387 4,349,672 13,778 4,983,729
------------ ------------ ------------ ------------ ------------
NET LOSS $ (620,279) $ (218,387) $ (4,349,672) $ (13,778) $ (4,983,729)
============ ============ ============ ============ ============
NET LOSS PER COMMON SHARE
(BASIC AND DILUTED) $ (0.02) $ (0.01) $ (0.14) $ (0.01) $ (0.15)
============ ============ ============ ============ ============
WEIGHTED AVERAGE COMMON
SHARES OUTSTANDING 37,879,948 27,825,448 30,866,730 27,410,000 33,191,625
============ ============ ============ ============ ============
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS.
F-3
MAZAL PLANT PHARMACEUTICAL, INC.
(Formerly AKID Corporation)
(A Development Stage Corporation)
STATEMENTS OF CASH FLOWS
For the Period For the Period
For the Six May 18, 2004 May 18, 2004
Months Ended For the (Inception) (Inception)
------------------------- Year Ended to to
June 30, June 30, December 31, December 31, June 30,
2006 2005 2005 2004 2006
----------- ----------- ------------ -------------- ---------------
(Unaudited) (Unaudited) (Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss $(620,279) $(218,387) $(4,349,672) $(13,778) $(4,983,729)
Adjustments to reconcile net loss to cash flows used
in operating activities:
Stock based compensation 324,000 5,855 3,732,137 312 4,056,449
Changes in operating assets and liabilities:
Decrease (increase) in prepaid
salaries - stockholders 21,668 (13,200) (31,550) (9,882)
Increase due from affiliated companies (6,717) (6,267) (12,984)
(Decrease) increase in accounts payable (10,532) 634 57,086 46,554
Increase in accrued expenses 54,773 25,069 40,567 633 95,973
Increase in accrued salaries - stockholders 16,382 4,600 17,918 12,100 46,400
Net Cash Used in Operating Activities (220,705) (195,429) (539,781) (733) (761,219)
CASH FLOWS FROM FINANCING ACTIVITIES
Advances from Advanced Plant Pharmaceuticals, Inc. 733 733
Payments due to Advanced Plant Pharmaceuticals, Inc. (34,422) (50,732) (50,732)
Proceeds from loan payable - stockholder 50,000 50,000 50,000
Proceeds from deposits to acquire stock 67,500 67,500
Proceeds from issuance of common stock 150,000 270,000 820,000
Costs paid in private placement of common stock (5,000) 552,000 (123,000)
Net Cash provided by Financing Activities 212,500 285,578 551,268 733 764,501
(DECREASE) INCREASE IN CASH (8,205) 90,149 11,487 32,282
CASH, BEGINNING OF PERIOD 11,487
CASH, END OF PERIOD $ 3,282 $ 90,149 $ 11,487 $ $ 32,282
SUPPLEMENTAL CASH FLOW INFORMATION:
Amount due to Advanced Plant Pharmaceutical, Inc.
for technology rights $ 50,000 $ 50,000
Issuance of common stock for technology rights $ 700 $ 700
Issuance of common stock as compensation $ 324,000 $ 5,855 $ 3,732,137 $ 312 $ 4,056,449
========= ========= =========== ======== ===========
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS.
F-4
MAZAL PLANT PHARMACEUTICAL, INC.
(Formerly AKID Corporation)
(A Development Stage Corporation)
STATEMENT OF STOCKHOLDERS' DEFICIT
For the Period May 18, 2004 (Inception) to June 30, 2006 (Unaudited)
Common Stock Additional Total
------------ Paid in Accumulated Stockholders'
Shares Amount Capital Deficit Deficit
------------------------------------------------------------------------------------
Mazal Plant Pharmaceutical, Inc. 10,130,000 $ 1,013 $ 1,013
----------- ----------- ----------- ----------- -----------
Total Mazal Plant Pharmaceutical,
Inc. prior to reverse merger 10,130,000 1,013 1,013
Reverse Merger
Merger with AKID Corporation
Cancellation of Mazal Plant
Pharmaceutical, Inc. common
stock (10,130,000) (1,013) $ 1,013
Equity of AKID Corporation 1,230,000 2,673 25,840 $ (28,513)
Issuance of 20,000,000 shares
in exchange for 7,000,000 shares
of Mazal 20,000,000
Issuance of 6,180,000 shares in
exchange for 3,130,000 shares
of Mazal 6,180,000
Capitalization of AKID net loss (26,853) 26,853
Net loss for the period May 18, 2004
(inception) to December 31, 2004 (13,778) (13,778)
----------- ----------- ----------- ----------- -----------
Balance, December 31, 2004 27,410,000 2,673 (15,438) (12,765)
Common stock issued January 2005
for services at $0.0001 156,000 16 16
Common stock issued March 2005
for services at $0.0001 100,000 10 10
Common stock issued April 6, 2005
for cash at $0.20 100,000 20,000 20,000
Common stock issued April 19, 2005
for services at $0.20 120,000 24,000 24,000
Common stock issued June 6, 2005
for services at $0.0658 600,000 39,480 39,480
Common stock issued June 30, 2005
for cash at $0.0658 3,800,000 250,000 250,000
Common stock issued August 1, 2005
for services at $0.0658 500,000 32,900 32,900
Common stock issued August 1, 2005
for cash at $0.417 120,000 50,000 50,000
Common stock issued September 26,
2005 for services at $0.417 200,000 83,400 83,400
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS.
F-5
MAZAL PLANT PHARMACEUTICAL, INC.
(Formerly AKID Corporation)
(A Development Stage Corporation)
STATEMENT OF STOCKHOLDERS' DEFICIT (CONTINUED)
For the Period May 18, 2004 (Inception) to June 30, 2006 (Unaudited)
Common Stock Additional Total
------------ Paid in Accumulated Stockholders'
Shares Amount Capital Deficit Deficit
-------------------------------------------------------------------------
Common stock issued September 26,
2005 for services at $0.417 200,000 83,400 83,400
Common stock issued September 26,
2005 for services at $0.417 50,000 20,850 20,850
Common stock issued October 31,
2005 for cash at $0.40 1,200,000 300,000 300,000
Costs incurred in private placement (118,000) (118,000)
Fair market value of 1,000,000
options issued with common stock
subscription 569,656 569,656
Common stock issued November 15,
2005 for services at $1.03 800,000 824,000 824,000
Common stock issued December 7,
2005 for services at $1.25 1,000,000 1,250,000 1,250,000
Common stock issued December 13,
2005 for cash at $0.40 200,000 50,000 50,000
Common stock issued December 15,
2005 for late registration filing at
$1.15 149,500 171,925 171,925
Common stock issued December 19,
2005 for services at $1.10 75,000 82,500 82,500
Common stock issued December 19,
2005 for late registration filing
at $1.10 500,000 550,000 550,000
Net loss for the year ended
December 31, 2005 (4,349,672) (4,349,672)
---------- ---------- ----------- -----------
Balance, December 31, 2005 37,280,500 4,286,810 (4,365,110) (78,300)
Common stock issued February 7,
2006 for services at $0.25 200,000 50,000 50,000
Costs incurred in private placement (5,000) (5,000)
Common stock issued April 11,
2006 for services at $0.25 400,000 100,000 100,000
Net loss for the three months
ended June 30, 2006 (620,279) (620,279)
---------- ---------- ----------- -----------
Balance, June 30, 2006 (unaudited) 38,180,500 $4,755,810 $(4,985,389) $ (229,579)
========== ========== =========== ===========
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS.
F-6
MAZAL PLANT PHARMACEUTICAL, INC.
(Formerly AKID Corporation)
(A Development Stage Corporation)
NOTES TO FINANCIAL STATEMENTS
December 31, 2005 and 2004
June 30, 2006 (Unaudited)
NOTE A - NATURE OF BUSINESS
Mazal Plant Pharmaceutical, Inc. (the "Company") has the technology rights
to develop, manufacture and distribute three products, specifically, plant
based compositions designed to treat elevated cholesterol, leukemia and
Alzheimer's disease.
Reverse Merger
On June 6, 2005, AKID Corporation ("AKID") entered into a stock exchange
agreement with Advanced Plant Pharmaceuticals, Inc. ("APPI") to acquire
7,000,000 shares of Mazal's common stock in exchange for 20,000,000 shares
of AKID common stock. AKID also acquired 3,130,000 shares of Mazal's
outstanding shares in exchange for 6,180,000 shares of its common stock.
In connection with the merger, Mazal became a wholly owned subsidiary of
AKID. Prior to the merger, AKID was a non-operating "shell" corporation.
Pursuant to Securities and Exchange Commission rules, the merger of a
private operating company, Mazal Plant Pharmaceutical, Inc. into a
non-operating public shell corporation with nominal net assets is
considered a capital transaction. At the time of the merger, the officers
and directors of AKID resigned and were replaced with the officers and
directors of Mazal. For Financial Statements presentation, the merger has
been reflected in the Financial Statements as though it occurred on
December 31, 2004. The historical statements prior to December 31, 2004
are those of Mazal Plant Pharmaceutical, Inc. Since the merger is a
recapitalization and not a business combination, pro forma information is
not presented. AKID subsequently filed a name change to Mazal Plant
Pharmaceutical, Inc.
Going Concern Uncertainty and Management's Plans
As reflected in the accompanying financial statements, the Company has
current liabilities in excess of current assets of $135,267, resulting in
negative working capital and an accumulated deficit of $4,635,110. The
Company had no revenues for the year ended December 31, 2005 and had costs
and expenses totaling $4,349,672. Management is presently seeking to raise
permanent equity capital in the capital markets to eliminate negative
working capital and provide working capital. Failure to raise equity
capital or secure some other form of long-term debt arrangement will cause
the Company to further increase its negative working capital deficit and
could result in the Company having to curtail or cease operations.
Additionally, even if the Company does raise sufficient capital to support
its operating expenses and generate revenues, there can be no assurances
that the revenue will be sufficient to enable it to develop business to a
level where it will generate profits and cash flows from operations. These
matters raise substantial doubt about the Company's ability to continue as
a going concern. However, the accompanying financial statements have been
prepared on a going concern basis, which contemplates the realization of
assets and satisfaction of liabilities in the normal course of business.
These financial statements do not include any adjustments relating to the
recovery of the recorded assets or the classification of the liabilities
that might be necessary should the Company be unable to continue as a
going concern.
F-7
MAZAL PLANT PHARMACEUTICAL, INC.
(Formerly AKID Corporation)
(A Development Stage Corporation)
NOTES TO FINANCIAL STATEMENTS
December 31, 2005 and 2004
June 30, 2006 (Unaudited)
NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash Equivalents
For purposes of reporting cash flows, cash equivalents include investment
instruments purchased with a maturity of three months or less. There are
no cash equivalents at June 30, 2006, December 31, 2005 and 2004.
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the
financial statements and reported amounts of revenues and expenses during
the reporting period. Actual results could differ from those estimates.
Net Loss Per Common Share
The Company computes per share amounts in accordance with Statement of
Financial Accounting Standards ("SFAS") No. 128, "Earnings per Share".
SFAS No. 128 requires presentation of basic and diluted EPS. Basic EPS is
computed by dividing the income (loss) available to common stockholders by
the weighted-average number of common shares outstanding for the period.
Diluted EPS is based on the weighted-average number of shares of common
stock and common stock equivalents outstanding during the period.
Stock-Based Compensation
SFAS No. 123, "Accounting for Stock-Based Compensation" prescribes
accounting and reporting standards for all stock-based compensation plans,
including employee stock options, restricted stock, employee stock
purchase plans and stock appreciation rights. SFAS No. 123 requires
employee compensation expense to be recorded (1) using the fair value
method or (2) using the intrinsic value method as prescribed by accounting
Principles Board Opinion No. 25, "Accounting for Stock Issued to
Employees" ("APB 25") and related interpretations with pro forma
disclosure of what net income and earnings per share would have been if
the Company adopted the fair value method. The Company accounts for
employee stock based compensation in accordance with the provisions of APB
25. For non-employee options and warrants, the company uses the fair value
method as prescribed in SFAS 123.
Income Taxes
The Company follows Financial Accounting Standards No. 109 (SFAS No. 109).
Under this method, the Company recognizes a deferred tax liability or
asset for temporary differences between the tax basis of an asset or
liability and the related amount reported on the financial statements. The
principal types of differences, which are measured at the current tax
rates, are net operating loss carry forwards. SFAS No. 109 requires the
establishment of a valuation allowance to reflect the likelihood of
realization of deferred tax assets.
F-8
MAZAL PLANT PHARMACEUTICAL, INC.
(Formerly AKID Corporation)
(A Development Stage Corporation)
NOTES TO FINANCIAL STATEMENTS
December 31, 2005 and 2004
June 30, 2006 (Unaudited)
NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Recent Accounting Pronouncements
In December 2004, the FASB issued Statement of Financial Accounting
Standards No. 153 (SFAS 153), "Exchanges of Non-monetary Assets." SFAS 153
amends the guidance in APB No. 29, "Accounting for Non-monetary Assets."
APB No.29 was based on the principle that exchanges of non-monetary assets
should be measured on the fair value of the assets exchanged. SFAS 153
amends APB No. 29 to eliminate the exception for non-monetary exchanges of
similar productive assets and replaces it with a general exception for
exchanges of non-monetary assets that do not have commercial substance if
the future cash flows of the entity are expected to change significantly
as a result of the exchange. SFAS 151 is effective for financial
statements issued for fiscal years beginning after June 15, 2005. The
adoption of SFAS 153 is not expected to have a material effect on the
Company's financial position or results of operations.
In December 2004, the FASB revised Statement of Financial Accounting
Standards No. 123 (SFAS 123(R)), "Accounting for Stock-Based
Compensation." The SFAS 123(R) revision established standards for the
accounting for transactions in which an entity exchanges its equity
instruments for goods or services and focuses primarily on accounting for
transactions in which an entity obtains employee services in share-based
payment transactions. It does not change the accounting guidance for
share-based payment transactions with parties other than employees. For
public entities that file as small business issuers, the revisions to SFAS
123(R) are effective as of the beginning of the first interim or annual
reporting period that begins after December 15, 2005. The adoption of SFAS
123(R) is not expected to have a material effect on the Company's
financial position or results of operations.
In May 2005, the FASB issued SFAS no. 154, "Accounting Changes and Error
Corrections ("SFAS No. 154") which replaces APB Opinion No. 20,
"Accounting Changes" and SFAS No. 3, "Reporting Accounting Changes in
Interim Financial Statements-An Amendment of ABP Opinion No. 28. SFAS No.
154 provides guidance on the accounting for and reporting of accounting
changes and error corrections. Specifically, this statement requires
"retrospective application" of the direct effect for a voluntary change in
accounting principle to prior periods' financial statements, if it is
practical to do so. SFAS No. 154 also strictly defines the term
"restatement" to mean the correction of an error revising previously
issued financial statements. SFAS No. 154 is effective for accounting
changes and corrections of errors made in fiscal years beginning after
December 15, 2005 and are required to be adopted by the Company in the
first quarter of fiscal year 2006. Although we will continue to evaluate
the application of SFAS No. 154, management does not anticipate that
adoption will have a material impact on our results of operations,
financial position or cash flows.
NOTE C - TECHNOLOGY RIGHTS
The technology rights include the rights to develop, manufacture, and
distribute plant based compositions designed to treat elevated
cholesterol, leukemia, and Alzheimer's disease. The Company acquired these
rights from Advanced Plant Pharmaceuticals, Inc. (hereafter referred to as
"APPI") for stock and a note payable aggregating $50,700. APPI is deemed
to be an affiliate of the Company.
F-9
MAZAL PLANT PHARMACEUTICAL, INC.
(Formerly AKID Corporation)
(A Development Stage Corporation)
NOTES TO FINANCIAL STATEMENTS
December 31, 2005 and 2004
June 30, 2006 (Unaudited)
NOTE D - RELATED PARTY TRANSACTIONS
At December 31, 2004, the Company was indebted to Advanced Plant
Pharmaceuticals, Inc. for $50,732 for the technology rights as
discussed in Note C to the Financial Statements. In 2005, the
Company made payments to APPI totaling $60,000 and paid expenses in
the amount of $5,749 on behalf of APPI. The Company was also
charged rent by APPI in the amount of $9,000. (See Note I) The
balance due from APPI amounted to $6,267 at December 31, 2005.
During the six months ended June 30, 2006, the Company paid
expenses of $2,217 on behalf of APPI resulting in a balance due
from APPI of $8,484 at June 30, 2006.
In January 2006, in connection with the monthly office lease
assumed from APPI (see Note I), the Company began charging $750 a
month rent to Amazon Biotech, Inc. ("Amazon"), an affiliated
company. At June 30, 2006, the amount due from Amazon was $4,500.
NOTE E - STOCKHOLDERS' DEFICIT
As discussed in the Reverse Merger (see Note A to the Financial
Statements), the exchange of Mazal shares for AKID, caused the Company to
exceed its authorized shares. The accompanying Financial Statements have
been prepared as though they were issued at December 31, 2004.
On October 31, 2005, the Company amended its Articles of Incorporation to
increase the total authorized shares of stock to 101,000,000 consisting of
100,000,000 shares of no par value common stock and 1,000,000 shares of no
par value preferred stock.
In October 2005, the Company authorized the 2005 Stock Compensation Plan
whereby 1,000,000 shares of common stock were reserved for awards to
employees, officers, directors, consultants and other individuals
providing services to the Company and its affiliates.
Issuance of common stock
In January 2005, the Company issued 50,000 shares of its common stock to
an employee at $0.0001 per share. The aggregate remuneration of $5 has
been treated as stock based compensation and expensed in the current year.
In January 2005, the Company issued 106,000 shares of its common stock to
a consultant at $0.0001 per share. The aggregate remuneration of $11 has
been treated as stock based compensation and expensed in the current year.
In March 2005, the Company issued 100,000 shares of its common stock to
its President at $0.0001 per share. The aggregate remuneration of $10 has
been treated as stock based compensation and expensed in the current year.
In connection with a private placement on April 6, 2005, the Company
issued 100,000 shares of its common stock at $0.20 per share realizing
$20,000.
F-10
MAZAL PLANT PHARMACEUTICAL, INC.
(Formerly AKID Corporation)
(A Development Stage Corporation)
NOTES TO FINANCIAL STATEMENTS
December 31, 2005 and 2004
March 31, 2006 (Unaudited)
NOTE E - STOCKHOLDERS' EQUITY (CONTINUED)
Issuance of common stock (Continued)
On April 19, 2005, the Company issued 120,000 shares of its common stock
to a consultant at $0.20 per share. The aggregate remuneration of $24,000
has been treated as stock based compensation and expensed in the current
year.
On June 6, 2005, the Company issued 600,000 shares of its common stock to
a consultant at $0.0658 per share. The aggregate remuneration of $39,480
has been treated as stock based compensation and expensed in the current
year.
In connection with a private placement on June 30, 2005, the Company
issued 3,800,000 shares of its common stock at $0.0658 per share realizing
$250,000.
On August 1, 2005, the Company issued 500,000 shares of its common stock
to an employee and major stockholder and founder of the Company at $0.0658
per share. The aggregate remuneration of $32,900 has been treated as stock
based compensation and expensed in the current year.
In connection with a private placement on August 1, 2005, the Company
issued 120,000 shares of its common stock at $0.417 per share realizing
$50,000.
In September, 2005, the Company issued 450,000 shares of its common stock
to consultants at $0.417 per share. The aggregate remuneration of $187,650
has been treated as stock based compensation and expensed in the current
year.
In connection with a private placement on October 31, 2005, the Company
issued 1,200,000 shares of its common stock at $0.40 per share realizing
$182,200 after deducting costs amounting to $118,000 incurred in
connection with the private placement. The Company also issued options to
purchase 1,000,000 shares of its common stock at an exercise price of
$0.50 per share and are exercisable for three years. Stock based
compensation of $569,656 has been recorded on the issuance of the options
and expensed in the current year.
On November 15, 2005, the Company issued 800,000 shares of its common
stock to a consultant at $1.03 per share. The aggregate remuneration of
$824,000 has been treated as stock based compensation and expensed in the
current year.
On December 7, 2005, the Company issued 1,000,000 shares of its common
stock to its former officers for consulting services at $1.25 per share.
The aggregate remuneration of $1,250,000 has been treated as stock based
compensation and expensed in the current year.
In connection with a private placement on December 13, 2005, the Company
issued 200,000 shares of its common stock at $0.40 per share realizing
$50,000.
On December 15, 2005, the Company issued 149,500 shares of its common
stock to a consultant at $1.15 per share. The aggregate remuneration of
$171,925 has been treated as stock based compensation and expensed in the
current year.
F-11
MAZAL PLANT PHARMACEUTICAL, INC.
(Formerly AKID Corporation)
(A Development Stage Corporation)
NOTES TO FINANCIAL STATEMENTS
December 31, 2005 and 2004
March 31, 2006 (Unaudited)
NOTE E - STOCKHOLDERS' EQUITY (CONTINUED)
Issuance of common stock (Continued)
On December 19, 2005, the Company issued 75,000 shares of its common stock
to its Chief Financial Officer at $1.10 per share. The aggregate
remuneration of $82,500 has been treated as stock based compensation and
expensed in the current year.
On December 19, 2005, the Company issued 500,000 shares of its common
stock to a consultant at $1.10 per share. The aggregate remuneration of
$550,000 has been treated as stock based compensation and expensed in the
current year.
On January 24, 2006, the Company issued 200,000 shares of its common stock
to a consultant at $1.08 per share. The aggregate remuneration of $216,000
has been treated as stock based compensation and expensed in the current
period.
On January 25 2006, the Company issued 100,000 shares of its common stock
to its President at $1.08 per share. The aggregate remuneration of
$108,000 has been treated as stock based compensation and expensed in the
current period.
On February 7, 2006, the Company approved the issuance of 200,000 shares
of its common stock at $0.25 per share pursuant to a private placement.
The Company incurred $5,000 in expenses related to the private placement
and realized $45,000.
On April 11, 2006, the Company approved the issuance of 400,000 shares of
its common stock at $0.25 per share pursuant to a private placement
realizing $100,000.
NOTE F - STOCK OPTIONS
The following table summarizes transactions in stock options through June
30, 2006:
Weighted Weighted
Average Average
Exercise Options Exercise
Options Price Exercisable Price
--------- -------- ----------- ---------
Granted
Exercised
Cancelled --------- ---------
Balance at December 31, 2004
Granted 1,000,000 $0.50 1,000,000 $0.50
Exercised
Cancelled --------- ---------
Balance at December 31, 2005 1,000,000 $0.50 1,000,000 $0.50
Granted
Exercised
Cancelled --------- ---------
Balance at June 30, 2006 1,000,000 $0.50 1,000,000 $0.50
========= =========
As of June 30, 2006, there were 1,000,000 common stock options outstanding
with a weighted average remaining life of 2.58 years and a weighted
average price of $0.50.
F-12
MAZAL PLANT PHARMACEUTICAL, INC.
(Formerly AKID Corporation)
(A Development Stage Corporation)
NOTES TO FINANCIAL STATEMENTS
December 31, 2005 and 2004
March 31, 2006 (Unaudited)
NOTE F - STOCK OPTIONS (CONTINUED)
Assumptions used to value stock options issued by the Company are as
follows:
For the
Years Ended
December 31,
-----------------
2005 2004
---- ----
Annual dividend No N/A
Volatility 10% N/A
Risk free interest rate 5% N/A
Expected life-years 3 N/A
During the year ended December 31, 2005, $569,656 of expense was recorded
on the issuance of stock options.
NOTE G - LOAN PAYABLE - STOCKHOLDER
The loan payable - stockholder represents a loan for working capital. The
loan is non-interest bearing and has no stated terms of repayment. The
balance at June 01, 2006, December 31, 2005 and 2004 amount to $50,000,
$50,000 and $0, respectively.
NOTE H - DEPOSIT TO ACQUIRE STOCK
The deposit to acquire stock at June 30, 2006, represents cash received
pursuant to a Securities Purchase Agreement for 200,000 shares of common
stock at $0.25 per share and an additional 400,000 shares of common stock
at $0.25 per share for which there is no written agreement. The deposit is
non-interest bearing. The balance at June 30, 2006 amounts to $150,000.
NOTE I - COMMITMENTS AND CONTINGENCIES
Employment Agreements
Between December 2004, as amended in August 2005, and November 2005, the
Company entered into six different employment contracts expiring between
July 2006 and December 2006. The contracts call for salaries ranging from
$1,100 to $5,500 per month. Two of the contracts call for issuances of
stock for the achievement of certain milestones.
Rent
In January 2005, the Company commenced sub-leasing its corporate office
space in New York, on a month to month basis, from APPI for $750 per
month.
In January 2006, the Company assumed making payments, from APPI, on its
corporate office space in New York. The monthly lease payment is $2,156
plus $25 a month for garbage disposal and 35% of the floor's electricity
cost.
F-13
MAZAL PLANT PHARMACEUTICAL, INC.
(Formerly AKID Corporation)
(A Development Stage Corporation)
NOTES TO FINANCIAL STATEMENTS
December 31, 2005 and 2004
March 31, 2006 (Unaudited)
NOTE I - COMMITMENTS AND CONTINGENCIES (CONTINUED)
Rent (continued)
Mazal maintains additional office space in Jerusalem, Israel on a month to
month basis at a monthly rent of $2,265 and a percentage of municipal
taxes.
From January 2005 to May 2005, the Company rented office space in the home
of the Company's President for a total amount of $12,000.
Net rent expense for the six months ended June 30, 2006 and 2005, the year
ended December 31, 2005 and for the period May 18, 2004 (Inception) to
June 30, 2006 amounted to $32918, $2,250, $30,500 and $63,418,
respectively. There was no rent expense for the period May 18, 2004
(inception) to December 31, 2004.
NOTE J- JOINT VENTURE AGREEMENT
On November 17, 2005, the Company executed a Letter of Intent to enter
into a possible joint venture with Punzi Medical Center ("PMC") in
connection with the Company's efforts to obtain approval of MAHDL, a
pharmaceutical drug currently under development by the Company, from the
United States Food and Drug Administration ("FDA"). The purpose of the
joint venture is to conduct Phase II and Phase III human clinical trials
of MAHDL and obtain the FDA's approval. Subject to the terms and
conditions of the agreement, PMC will (a) fund all costs and expenses
incurred in connection with the clinical trials, (b) make its facilities
available for the conduct of the clinical trials, and (c) provide
consulting services to the Company with respect to the conduct of the
clinical trials and their approval by the FDA. In consideration for the
obligations of PMC, the Company will pay royalties equal to an agreed upon
percentage of the net revenues generated by any sales of MAHDL to PMC
during an agreed upon time period following the FDA's final approval.
NOTE K - SUBSEQUENT EVENT
On July 1, 2006, the Company authorized the issuance of 244,000 shares of
its common stock for cash at $0.25 per share realizing $61,000.
On July 11, 2006, the Company amended its 2005 Stock Compensation Plan to
allow for the issuance of 3,500,000 shares, an increase of 2,500,000
shares.
On July 17, 2006, the Company entered into a consulting agreement whereby
the consultant is to introduce medical clinics and assist in the
development of clinical trials for the Company for a term of one year.
Either party may terminate the contract with or without cause upon thirty
days written notice. The agreement calls for the issuance of 500,000
shares of the Company's common stock upon signing and 1,500,000 shares of
the Company's common stock upon the Company receiving a letter of intent
from a medical center that has previously performed clinical trials for a
major pharmaceutical company, to perform clinical trials at competitive
rates, in which at least one third (33%) of the payment shall be in shares
of the Company's common stock.
On July 31, 2006, the Company entered into an Interim Letter of Agreement
for a Phase I/II, double-blind, placebo and active-controlled, randomized,
parallel-group study to evaluate the safety and efficacy of MAHDL01 alone
and as an adjunct to statin therapy, versus placebo or statin therapy
alone, in increasing HDL in subjects with hypoalphalipoproteinemia who are
maintaining a restricted diet. The agreement calls for a minimum number of
subjects of ten and a maximum of four hundred. The Company is responsible
for all external direct trial expenses. The consultant will receive $2,500
per subject who completes the study, where fifty percent (50%) will be
paid in cash and the remaining fifty percent (50%) will be paid in shares
of the Company's common stock.
NOTE L - RECLASSIFICATIONS
Certain amounts in 2004 financial statements have been reclassified to
conform to the classifications used in 2005.
F-14
PART II - INFORMATION NOT REQUIRED IN PROSPECTUS
INDEMNIFICATION OF DIRECTORS AND OFFICERS
Nevada law provides for discretionary indemnification made by the corporation
only as authorized in the specific case upon a determination that
indemnification of the director, officer, employee or agent is proper in the
circumstances. The determination must be made either: (i) by the stockholders;
(ii) by the board of directors by majority vote of a quorum consisting of
directors who were not parties to the action, suit or proceeding; (iii) if a
majority vote of a quorum consisting of directors who were not parties to the
actions, suit or proceeding so orders, by independent legal counsel in a written
opinion; or (iv) if a quorum consisting of directors who were not parties to the
action, suit or proceeding cannot be obtained, by independent legal counsel in a
written opinion. The Articles of Incorporation, the bylaws or an agreement made
by the corporation may provide that the expenses of officers and directors
incurred in defending a civil or criminal action, suit or proceeding must be
paid by the corporation as they are incurred and in advance of the final
disposition of the actions, suit or proceeding, upon receipt of an undertaking
by or on behalf of the director or officer to repay the amount if it is
ultimately determined by a court of competent jurisdiction that he is not
entitled to be indemnified by the corporation. The provisions do not affect any
right to advancement of expenses to which corporate personnel other than
directors or officers may be entitled under any contract or otherwise by law.
The indemnification and advancement of expenses authorized in or ordered by a
court pursuant to Nevada law does not exclude any other rights to which a person
seeking indemnification or advancement of expenses may be entitled under the
Articles of Incorporation or any bylaw, agreement, vote of stockholders or
disinterested directors or otherwise, for either an action in his or her
official capacity or an action in another capacity while holding office, except
that indemnification, unless ordered by a court or for the advancement of
expenses, may not be made to or on behalf of any director or officer if his or
her acts or omissions involved intentional misconduct, fraud or a knowing
violation of the law and were material to the cause of action. In addition,
indemnification continues for a person who has ceased to be a director, officer,
employee or agent and inures to the benefit of the heirs, executors and
administrators of such a person.
ITEM 25. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.
The following table sets forth the expenses in connection with the issuance and
distribution of the securities being registered hereby. All such expenses will
be borne by the registrant; none shall be borne by any selling stockholders.
- --------------------------------------------------------------------------------
Securities and Exchange
Commission registration fee........................... $
Legal fees and expenses (1)........................... 32,000
Accounting fees and expenses (1)...................... 6,500
Printing expenses ...............................2,500
State and Federal taxes ..............................
Miscellaneous (1)..................................... 2,500
-----------------------
Total (1).......................................43,500 $
=======================
- --------------------------------------------------------------------------------
(1) Estimated.
II-1
RECENT SALES OF UNREGISTERED SECURITIES
During the past three years, we have issued the following securities without
registration under the Securities Act of 1933:
In January 2005 we issued to Barry Ginsberg 106,000 shares of our common stock,
as consideration for his finder services to us in connection with the reverse
merger between Akid Corporation and Delaware Mazal. The shares were issued
under Section 4(2) of the Securities Act of 1933, as amended, and/or Regulation
D promulgated by the Securities and Exchange Commission.
In January 2005 we issued to Bernard Harris 50,000 shares of our common stock,
as consideration for his employment services to us as head of regulatory
affairs. The shares were issued under Section 4(2) of the Securities Act of
1933, as amended, and/or Regulation D promulgated by the Securities and Exchange
Commission.
On March 15, 2005, we authorized the issuance of 100,000 shares of our common
stock to Dr. Mechael Kanovsky in consideration for his employment services
rendered to the Delaware Mazal, our subsidiary. We issued the shares to Dr.
Mechael Kanovsky on December 19, 2005. The shares were authorized to be issued
under Section 4(2) of the Securities Act of 1933, as amended, and/or Regulation
D promulgated by the Securities and Exchange Commission.
On April 6, 2005 we authorized the issuance of and on August 1, 2005, we issued
to Debbie Gushlak 100,000 shares of our common stock in a private placement at
$0.20 per share realizing $20,000. The shares were issued under Regulation S
promulgated by the Securities and Exchange Commission.
On April 19, 2005, we issued 60,000 shares of our common stock to each of Harvey
Hecht and Matthew Pincus in consideration for their participation on our
scientific board. The aggregate remuneration of $24,000 has been treated as
stock based compensation and expensed in the current year. The shares were
authorized to be issued under Section 4(2) of the Securities Act of 1933, as
amended, and/or Regulation D promulgated by the Securities and Exchange
Commission.
On June 6, 2005, upon the consummation of the transactions contemplated by the
Share Exchange Agreement, we became contractually obligated to issue 20,000,000
shares of common stock to Advanced Plant Pharmaceuticals, Inc., a Delaware
corporation. In consideration for such issuance, we acquired from Advanced Plant
Pharmaceuticals, Inc. its entire ownership interest in 7,000,000 shares of the
common stock of Delaware Mazal, which represented 69% of the issued and
outstanding shares of Delaware Mazal. The shares were issued under Section 4(2)
of the Securities Act of 1933, as amended, and/or Regulation D promulgated by
the Securities and Exchange Commission.
On June 6, 2005, we issued to Ronnie Yacov 600,000 shares of our common stock,
as consideration for his finder services to us. We granted to the consultant
piggy-back registration rights with respect to 60,000 of his shares. The shares
were issued under Section 4(2) of the Securities Act of 1933, as amended, and/or
Regulation D promulgated by the Securities and Exchange Commission.
II-2
On June 30, 2005, we issued to Malcolm Jennings 3,800,000 shares of our common
stock in a private placement at $0.0658 per share realizing $250,000. The shares
were issued under Regulation S promulgated by the Securities and Exchange
Commission.
On August 1, 2005, we authorized the issuance 500,000 shares of our common stock
to Chaim J. Lieberman for his business development services rendered to the
Delaware Mazal, our subsidiary. The shares were authorized to be issued under
Section 4(2) of the Securities Act of 1933, as amended, and/or Regulation D
promulgated by the Securities and Exchange Commission.
On August 1, 2005, we issued to Leonard Cohen 120,000 shares of our common stock
in a private placement at $0.417 per share of common stock realizing $50,000. We
granted to Mr. Cohen piggy-back registration rights with respect to 60,000 of
his shares, meaning that we must include such shares in a registration statement
that we may file with the Securities and Exchange Commission. The shares were
issued under Regulation S promulgated by the Securities and Exchange Commission.
On September 26, 2005, we issued to Imperial Consulting Network 200,000 shares
of our common stock for services rendered by Performance Profiler Quarterly in
connection with the preparation and publication of an article relating to us.
The shares were issued under Section 4(2) of the Securities Act of 1933, as
amended, and/or Regulation D promulgated by the Securities and Exchange
Commission.
On September 26, 2005, we issued to Golden Key 200,000 shares of our common
stock for services rendered by Performance Profiler Quarterly in connection with
the preparation and publication of an article relating to us. The shares were
issued under Section 4(2) of the Securities Act of 1933, as amended, and/or
Regulation D promulgated by the Securities and Exchange Commission.
On September 26, 2005, we authorized the issuance of and issued to Dr. Robert
Segal on January 25, 2006 50,000 shares of our common stock for advisory
services rendered to us. The shares were issued under Section 4(2) of the
Securities Act of 1933, as amended, and/or Regulation D promulgated by the
Securities and Exchange Commission.
On October 31, 2005, we issued to Mr. Luc Verelest 1,200,000 shares of our
common stock and warrants to purchase 1,000,000 shares of our common stock at an
exercise price of $0.50 in consideration for $300,000. The shares were issued
under Regulation S promulgated by the Securities and Exchange Commission.
On December 7, 2005, we authorized and issued on January 5, 2006 to each of
James B. Wiegand and Max Gould 500,000 shares which were issued as consideration
for their consulting services provided to us during the merger. We granted to
Mr. Wiegand and Mr. Gould piggy-back registration rights with respect to 50,000
of each of their shares. The shares were issued under Section 4(2) of the
Securities Act of 1933, as amended, and/or Regulation D promulgated by the
Securities and Exchange Commission.
II-3
On December 13, 2005 we authorized and on January 24, 2006, we issued to Mr.
Malcolm Jennings 200,000 shares of our common stock in consideration for
$50,000. The shares were issued under Regulation S promulgated by the Securities
and Exchange Commission.
On December 15, 2005 we authorized the issuance to Mr. Malcolm Jennings 149,500
shares of our common stock for late registration of our common stock. The shares
were issued pursuant to the Subscription Agreement which stated that if Mazal
fails the registration statement within 30 business days after the date of the
Subscription Agreement then Mazal will issue periodically 100,000 shares for
each 20 day period of delay. The shares were issued under Regulation S
promulgated by the Securities and Exchange Commission.
On December 19, 2005, we issued to Simcha Edell 75,000 shares of our common
stock for employment services provided to us. The shares were issued under
Section 4(2) of the Securities Act of 1933, as amended, and/or Regulation D
promulgated by the Securities and Exchange Commission.
On December 19, 2005, we issued to Malcolm Jennings 500,000 shares of our common
stock as a penalty for a late registration filing. The shares were issued under
Regulation S promulgated by the Securities and Exchange Commission.
On January 25, 2006, we issued 100,000 shares of our common stock to Dr. Mechael
Kanovsky as a performance bonus. The shares were authorized to be issued under
Section 4(2) of the Securities Act of 1933, as amended, and/or Regulation D
promulgated by the Securities and Exchange Commission.
On February 7, 2006, we authorized the issuance of 200,000 shares of its common
stock to Malcolm Jennings, at $0.25 per share pursuant to a private placement.
The shares were issued under Regulation S promulgated by the Securities and
Exchange Commission
On April 25, 2006, we issued 400,000 shares of our common stock to Malcolm
Jennings at $0.25 per share pursuant to a private placement in consideration for
$100,000. The shares were issued under Regulation S promulgated by the
Securities and Exchange Commission.
On July 1, 2006, we issued 244,000 shares of our common stock to Malcolm
Jennings at $0.25 per share pursuant to a private placement in consideration for
$61,000. The shares were issued under Regulation S promulgated by the Securities
and Exchange Commission.
On September 6, 2006, we issued 100,000 shares of our common stock to Malcolm
Jennings at $0.25 per share pursuant to a private placement in consideration for
$25,000. The shares were issued under Regulation S promulgated by the Securities
and Exchange Commission
On September 6, 2006, we authorized the issuance of and issued to Dr. Robert
Segal on January 25, 2006 50,000 shares of our common stock for advisory
services rendered to us as a member of our scientific board. The shares were
issued under Section 4(2) of the Securities Act of 1933, as amended, and/or
Regulation D promulgated by the Securities and Exchange Commission.
EXHIBITS AND FINANCIAL STATEMENTS
(a) Exhibits:
The following exhibits are filed as part of this registration statement:
EXHIBIT
NUMBER DESCRIPTION WHERE FOUND
- ------ ----------- -----------
3.1 Articles of Incorporation Provided herewith.
3.2 By-Laws Provided herewith.
4.1 Warrant Provided herewith.
5.1 Opinion regarding the legality of the will be provided.
securities being registered
10.1 Share Exchange Agreement, dated May Previously filed with our Current Report on Form
2005, among Advanced Plant 8-K, dated June 6, 2005, filed with the SEC on June
Pharmaceuticals, Inc., James B. 9, 2005 and incorporated herein by reference.
Wiegand and us
10.2 Employment Agreement, dated Previously filed with our Annual Report on Form
December 10, 2004, as amended on 10-KSB for the fiscal year ended April 30, 2005,
August 1, 2005, among Mechael filed with the SEC on August 11, 2005 and
Kanovsky, Mazal, and Delaware incorporated herein by reference.
Mazal
II-4
10.3 Employment Agreement, dated Previously filed with our Annual Report on Form
December 10, 2004, as amended on 10-KSB for the fiscal year ended April 30, 2005,
August 1, 2005, among Sam filed with the SEC on August 11, 2005 and
Berkowitz, Mazal, and incorporated herein by reference.
Delaware Mazal
10.4 Employment Agreement, dated Provided herewith.
December 10, 2004, as amended on
August 1, 2005, among Chaim J.
Lieberman, Mazal, and
Delaware Mazal
10.5 Employment Agreement, dated Provided herewith.
December 10, 2004, as amended on
August 1, 2005, among David
Lieberman, Mazal, and
Delaware Mazal
10.6 Subscription Agreement, dated May Provided herewith.
19, 2005, between Mazal and
Malcolm Jennings
10.7 Share Exchange Agreement, dated April Provided herewith.
11, 2005, between Mazal and
Leonard Cohen
10.8 Share Exchange Agreement, dated April Provided herewith.
11, 2005, between Mazal and
Halcyon SA
10.9 Letter Agreement, dated May 11, 2005, Previously filed with our Current Report
between Delaware Mazal and on Form 8-K, dated June 6, 2005, filed with
Corporate Management Services, Inc. the SEC on June 9, 2005 and incorporated
herein by reference.
10.10 Letter of Intent with Punzi Medical Provided herewith.
Center dated November 17, 2005.
16.1 Letter on change in certifying Previously filed with our Current Report on Form
accountant 8-K, dated August 12, 2005, filed with the SEC on
August 12, 2005 and incorporated herein by reference.
21.1 Subsidiaries Provided herewith.
23.1 Consent of Meyler & Co. to be provided.
23.2 Consent of [insert] to be provided
(included in Exhibit 5.1).
UNDERTAKINGS
(A) The undersigned Registrant hereby undertakes:
II-5
(1) To file, during any period in which offers or sales are being made,
a post-effective amendment to this registration statement to:
(i) Include any prospectus required by Section 10(a)(3) of the
Securities Act of 1933 ("Act");
(ii) Reflect in the prospectus any facts or events arising after
the Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate,
represent a fundamental change in the information set forth in
the Registration Statement. Notwithstanding the foregoing, any
increase or decrease in volume of securities offered (if the
total dollar value of securities offered would not exceed that
which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected
in the form of prospectus filed with the Commission pursuant
to Rule 424(b) if, in the aggregate, the changes in volume and
price represent no more than 20 percent change in the maximum
aggregate offering price set forth in the "Calculation of
Registration Fee" table in the effective Registration
Statement; and
(iii) Include any material information or changed material
information on the plan of distribution.
(2) That, for the purpose of determining any liability under the Act,
each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein,
and the offering therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering
thereof.
(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the
end of the offering.
(B) Undertaking Required by Regulation S-B, Item 512(e).
Insofar as indemnification for liabilities arising under the Act may be
permitted to directors, officers or controlling persons pursuant to the
foregoing provisions, or otherwise, the Registrant has been advised that in the
opinion of the Securities and Exchange Commission such indemnification is
against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other
than the payment by the Registrant of expenses incurred or paid by a director,
officer or controlling person of the Registrant in the successful defense of any
action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the Registrant will,
unless in the opinion of its counsel that the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as
expressed in the Act and will be governed by the final adjudication of such
issue.
II-6
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has
duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of New York, State of New
York, on the _ day of December, 2006.
MAZAL PLANT PHARMACEUTICALS, INC.
/s/Mechael Kanovsky
-----------------------------
Mechael Kanovsky
Director and
Chief Executive Officer
(principal executive officer)
/s/Simcha Edell
-----------------------------
Simcha Edell
Chief Financial Officer
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below
constitutes and appoints Mechael Kanovsky, and each or either
of them, his or her true and lawful attorneys-in-fact, with full power of
substitution and resubstitution, for him or her and in his or her name, place
and stead, in any and all capacities to sign any and all amendments (including
post-effective amendments) to this registration statement and to sign a
registration statement pursuant to Section 462(b) of the Securities Act of 1933,
and to file the same with all exhibits thereto, and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto
said attorneys-in-fact, full power and authority to do and perform each and
every act and thing requisite and necessary to be done in and about the
premises, as fully to all intents and purposes as he might or could do in
person, hereby ratifying and confirming all that said attorneys-in-fact or his
substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration
statement has been signed by the following persons in the capacities and on the
dates indicated.
SIGNATURE TITLE DATE
/s/ Mechael Kanovsky Chief Executive Officer December 21, 2006
- ------------------------ and Director
Mechael Kanovsky
/s/ Simcha Edell Chief Financial Officer December 21, 2006
- ------------------------
Simcha Edell
II-7